

Deepak L Bhatt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3007388/publications.pdf>

Version: 2024-02-01

1,229
papers

114,537
citations

268

141
h-index

232

305
g-index

1257
all docs

1257
docs citations

1257
times ranked

60346
citing authors

#	ARTICLE	IF	CITATIONS
1	Editorial commentary: Weight loss for cardiovascular disease prevention “is semaglutide the answer?”. Trends in Cardiovascular Medicine, 2023, 33, 167-169.	4.9	1
2	Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis. Minerva Cardiology and Angiology, 2023, 71, .	0.7	6
3	Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 216-226.	3.0	23
4	Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. Gut, 2022, 71, 254-264.	12.1	37
5	Association of inflammatory disease and long-term outcomes among young adults with myocardial infarction: the Mass General Brigham YOUNG-MI Registry. European Journal of Preventive Cardiology, 2022, 29, 352-359.	1.8	10
6	Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 462-473.	3.0	8
7	Predictors of angina resolution after percutaneous coronary intervention in stable coronary artery disease. Coronary Artery Disease, 2022, 33, 98-104.	0.7	1
8	Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective. American Journal of Cardiovascular Drugs, 2022, 22, 93-104.	2.2	5
9	Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. Cardiovascular Research, 2022, 118, 2231-2252.	3.8	23
10	Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI. Journal of Thrombosis and Thrombolysis, 2022, 53, 380-389.	2.1	4
11	Bleeding avoidance strategies in percutaneous coronary intervention. Nature Reviews Cardiology, 2022, 19, 117-132.	13.7	71
12	Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE“TIMI 58 trial. European Heart Journal, 2022, 43, 2958-2967.	2.2	28
13	Rationale and pathways forward in the implementation of coronary artery calcium-based enrichment of randomized trials. American Heart Journal, 2022, 243, 54-65.	2.7	3
14	Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides. Expert Opinion on Drug Safety, 2022, 21, 31-42.	2.4	7
15	A randomized trial comparing axillary versus innominate artery cannulation for aortic arch surgery. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 1426-1438.e2.	0.8	17
16	Vascular repair and regeneration in cardiometabolic diseases. European Heart Journal, 2022, 43, 450-459.	2.2	8
17	Sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a systematic review and meta-analysis of randomized trials. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 383-390.	4.0	9
18	Cardiac involvement in the long-term implications of COVID-19. Nature Reviews Cardiology, 2022, 19, 332-341.	13.7	83

#	ARTICLE	IF	CITATIONS
19	Virtual and Augmented Reality in Cardiovascular Care. JACC: Cardiovascular Imaging, 2022, 15, 519-532.	5.3	34
20	Population pharmacokineticâ€“pharmacodynamic modeling of PB2452, a monoclonal antibody fragment being developed as a ticagrelor reversal agent, in healthy volunteers. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 68-81.	2.5	4
21	In-Stent Restenosis in Saphenous Vein Grafts (from the DIVA Trial). American Journal of Cardiology, 2022, 162, 24-30.	1.6	4
22	The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. Cardiovascular Drugs and Therapy, 2022, 36, 561-567.	2.6	16
23	Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity?. American Heart Journal, 2022, 244, 135-148.	2.7	10
24	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. Journal of Cardiovascular Computed Tomography, 2022, 16, 54-122.	1.3	57
25	Ten-Year Trends in Patient Characteristics, Treatments, and Outcomes in Myocardial Infarction From National Cardiovascular Data Registry Chest Painâ€“MI Registry. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, e008112.	2.2	13
26	Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS120010390.	3.9	4
27	Relationship Between Myocardial Injury During Index Hospitalization for SARSâ€“CoVâ€“2 Infection and Longerâ€“Term Outcomes. Journal of the American Heart Association, 2022, 11, e022010.	3.7	24
28	In NSTEMI, are patients without SMuRFs real?. European Journal of Preventive Cardiology, 2022, 29, 1081-1083.	1.8	3
29	Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. Diabetes Care, 2022, 45, 938-946.	8.6	20
30	Association Between Endovascular Therapy Time to Treatment and Outcomes in Patients With Basilar Artery Occlusion. Circulation, 2022, 145, 896-905.	1.6	9
31	Impact of the COVID-19 Pandemic on Non-COVID-19 Clinical Trials. Journal of Cardiovascular Development and Disease, 2022, 9, 19.	1.6	16
32	Potential Impact of the 2019 ACC/AHA Guidelines on the Primary Prevention of Cardiovascular Disease Recommendations on the Inappropriate Routine Use of Aspirin and Aspirin Use Without a Recommended Indication for Primary Prevention of Cardiovascular Disease in Cardiology Practices: Insights From the NCDR PINNACLE Registry. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, CIRCOOUTCOMES121007979.	2.2	7
33	Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT. Journal of the American College of Cardiology, 2022, 79, 220-222.	2.8	14
34	Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation. Clinical Pharmacokinetics, 2022, 61, 465-479.	3.5	14
35	Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. New England Journal of Medicine, 2022, 386, 316-326.	27.0	640
36	Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm. European Heart Journal, 2022, 43, 1715-1727.	2.2	40

#	ARTICLE	IF	CITATIONS
37	The year in cardiovascular medicine 2021: diabetes and metabolic disorders. European Heart Journal, 2022, 43, 263-270.	2.2	7
38	Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. Circulation, 2022, 145, CIR0000000000001040.	1.6	193
39	Response to the Letter on "The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus" Cardiovascular Drugs and Therapy, 2022, , 1.	2.6	0
40	Early and late recurrent cardiovascular events among high-risk patients with an acute coronary syndrome: Meta-analysis of phase III studies and implications on trial design. Clinical Cardiology, 2022, , .	1.8	3
41	Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. Diabetes Care, 2022, 45, e27-e29.	8.6	10
42	Prevalence and Prognostic Significance of Polyvascular Disease in Patients Hospitalized With Acute Decompensated Heart Failure: The ARIC Study. Journal of Cardiac Failure, 2022, 28, 1267-1277.	1.7	3
43	Socioeconomic disparities in healthcare utilization for atherosclerotic cardiovascular disease. American Heart Journal, 2022, 246, 161-165.	2.7	2
44	Trends in 30-Day and 90-Day Readmission Rates After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2022, , .	1.6	0
45	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2022, 36, 108101.	2.3	23
46	Abstract WP210: Eicosapentaenoic Acid (EPA) Decreases Cytokine Release And Inflammatory Proteins In Brain Vascular Endothelium During Inflammation. Stroke, 2022, 53, .	2.0	0
47	Abstract WP229: Eicosapentaenoic Acid (EPA) Modulates Expression Of Thrombotic And Metabolic Proteins In Brain Endothelium Following Cytokine Challenge. Stroke, 2022, 53, .	2.0	1
48	The early reduction of left ventricular mass after sleeve gastrectomy depends on the fall of branched-chain amino acid circulating levels. EBioMedicine, 2022, 76, 103864.	6.1	10
49	Geriatric and Palliative Care Specialists as Valued Members of the Multidisciplinary Heart Team. American Journal of Medicine, 2022, 135, 810-812.	1.5	2
50	Seasonal Variation of Atrial Fibrillation Admission and Quality of Care in the United States. Journal of the American Heart Association, 2022, 11, e023110.	3.7	5
51	Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery. , 2022, 1, .		13
52	Diagnosis and Treatment of Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2022, 327, 662.	7.4	219
53	Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA Network Open, 2022, 5, e2148172.	5.9	11
54	Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCl. Journal of the American Heart Association, 2022, 11, e022937.	3.7	26

#	ARTICLE	IF	CITATIONS
55	Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011069.	3.9	0
56	Circulating linoleic acid at the time of myocardial infarction and risk of primary ventricular fibrillation. <i>Scientific Reports</i> , 2022, 12, 4377.	3.3	2
57	Balance of Benefit and Risk of Ticagrelor in Patients With Diabetes and Stable Coronary Artery Disease According to Bleeding Risk Assessment With the CRUSADE Score: Data From THEMIS and THEMIS PCI. <i>American Heart Journal</i> , 2022, 249, 23-23.	2.7	1
58	P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials. <i>European Heart Journal Open</i> , 2022, 2, .	2.3	18
59	Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Randomized Trial. <i>American Journal of Medicine</i> , 2022, , .	1.5	0
60	Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention. <i>Current Cardiology Reports</i> , 2022, 24, 277-293.	2.9	3
61	Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121009099.	3.9	14
62	Secular Trends in Prevalence of Heart Failure Diagnosis over 20 Years (from the US NHANES). <i>American Journal of Cardiology</i> , 2022, , .	1.6	4
63	Evaluation of Evidence-Based Dual Antiplatelet Therapy for Secondary Prevention in US Patients With Acute Ischemic Stroke. <i>JAMA Internal Medicine</i> , 2022, 182, 559.	5.1	6
64	Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT. <i>Journal of the American Heart Association</i> , 2022, 11, e024999.	3.7	13
65	Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 330-340.	11.4	19
66	Generalizability of FIGARO-CKD and FIDELIO-CKD Trial Criteria to the US Population Eligible for Finerenone. <i>Journal of the American Heart Association</i> , 2022, 11, e025079.	3.7	7
67	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 786-795.	3.0	6
68	Perioperative Management of P2Y12 Inhibitors in Patients Undergoing Cardiac Surgery within 1 Year of PCI. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, , .	3.0	2
69	Design and rationale for the supermarket and web-based intervention targeting nutrition (SuperWIN) for cardiovascular risk reduction trial. <i>American Heart Journal</i> , 2022, 248, 21-34.	2.7	4
70	Intensive blood pressure control in patients with a history of heart failure: the Systolic Blood Pressure Intervention Trial (SPRINT). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, E12-E14.	3.0	5
71	Alirocumab after acute coronary syndrome in patients with a history of heart failure. <i>European Heart Journal</i> , 2022, 43, 1554-1565.	2.2	23
72	Prognostic implications of serial high-sensitivity cardiac troponin testing among patients with COVID-19: A Danish nationwide registry-based cohort study. <i>American Heart Journal Plus</i> , 2022, 14, 100131.	0.6	3

#	ARTICLE	IF	CITATIONS
73	Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin Following WATCHMAN in High-Risk Patients. , 2022, , 100042.		2
74	No Diagnostic Concerns With Cardiovascular Magnetic Resonance Imaging in Patients With Breast Cancer and Breast Implantsâ€”Reply. JAMA Cardiology, 2022, 7, 655.	6.1	1
75	Evaluating the evaluators - Developing evidence of quality oversight effectiveness for clinical trial monitoring: Source data verification, source data review, statistical monitoring, key risk indicators, and direct measure of high risk errors. Contemporary Clinical Trials, 2022, 117, 106764.	1.8	3
76	Has Unstable Angina Become a Vestigial of the Past in Clinical Trial Primary Endpoints?. Cardiology, 2022, , .	1.4	0
77	A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial. EuroIntervention, 2022, 18, e292-e302.	3.2	5
78	Association of Influenza Vaccination With Cardiovascular Risk. JAMA Network Open, 2022, 5, e228873.	5.9	61
79	The National Cardiovascular Data Registry Data Quality Program 2020. Journal of the American College of Cardiology, 2022, 79, 1704-1712.	2.8	15
80	Machine learning based model for risk prediction after ST-Elevation myocardial infarction: Insights from the North India ST elevation myocardial infarction (NORIN-STEMI) registry. International Journal of Cardiology, 2022, 362, 6-13.	1.7	4
81	Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, 2022, 145, 1581-1591.	1.6	13
82	Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2022, 100, 72-82.	1.7	4
83	Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. Journal of the American College of Cardiology, 2022, 79, 1660-1671.	2.8	36
84	The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl. American Journal of Preventive Cardiology, 2022, 10, 100345.	3.0	4
85	Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction. Journal of the American College of Cardiology, 2022, 79, 2058-2068.	2.8	41
86	Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. American Heart Journal, 2022, 253, 86-98.	2.7	48
87	Sameâ€”Day Discharge After Transcatheter Aortic Valve Implantation: Insights from the Nationwide Readmission Database 2015 to 2019. Journal of the American Heart Association, 2022, 11, .	3.7	5
88	Cangrelor Use Patterns and Transition to Oral P2Y₁₂ Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry. Journal of the American Heart Association, 2022, 11, .	3.7	4
89	A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes. Prostaglandins Leukotrienes and Essential Fatty Acids, 2022, 182, 102450.	2.2	14
90	Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES. Canadian Journal of Cardiology, 2022, 38, 1542-1549.	1.7	4

#	ARTICLE	IF	CITATIONS
91	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. JAMA Cardiology, 2022, 7, 747.	6.1	15
92	Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT. Journal of Clinical Lipidology, 2022, 16, 389-402.	1.5	7
93	Causes, Angiographic Characteristics, and Management of Premature Myocardial Infarction. Journal of the American College of Cardiology, 2022, 79, 2431-2449.	2.8	30
94	EPA Versus Mixed EPA/DHA Plus Statin for Coronary Atherosclerosis. JACC: Cardiovascular Imaging, 2022, , .	5.3	2
95	Left-Sided Degenerative Valvular Heart Disease in Type 1 and Type 2 Diabetes. Circulation, 2022, 146, 398-411.	1.6	10
96	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nature Reviews Cardiology, 2022, 19, 829-844.	13.7	30
97	Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. European Journal of Preventive Cardiology, 2022, 29, 1842-1851.	1.8	7
98	Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. European Heart Journal, 2022, 43, 2931-2945.	2.2	14
99	Costs of Endoscopic vs Open Vein Harvesting for Coronary Artery Bypass Grafting. JAMA Network Open, 2022, 5, e2217686.	5.9	0
100	Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. Circulation, 2022, 145, 1875-1877.	1.6	1
101	Omega-3 fatty acids, subclinical atherosclerosis, and cardiovascular events: Implications for primary prevention. Atherosclerosis, 2022, 353, 11-19.	0.8	8
102	Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. European Heart Journal, 2022, 43, 3542-3552.	2.2	7
103	Association Between Periodontal Disease and Cardiovascular Disease (from the NHANES). American Journal of Cardiology, 2022, 178, 163-168.	1.6	13
104	Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stents. Catheterization and Cardiovascular Interventions, 2021, 98, 1111-1119.	1.7	2
105	Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in <sc>DECLARE-TIMI</sc> 58. European Journal of Heart Failure, 2021, 23, 1026-1036.	7.1	35
106	Atherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry. European Journal of Preventive Cardiology, 2021, 28, e12-e14.	1.8	8
107	Targeting cardiovascular inflammation: next steps in clinical translation. European Heart Journal, 2021, 42, 113-131.	2.2	186
108	Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results. Cardiovascular Research, 2021, 117, 1070-1077.	3.8	45

#	ARTICLE	IF	CITATIONS
109	Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis. American Heart Journal, 2021, 232, 105-115.	2.7	15
110	Reduction in Revascularization With Icosapent Ethyl. Circulation, 2021, 143, 33-44.	1.6	46
111	Impact of chronic kidney disease on in-hospital outcomes and readmission rate after edge-to-edge transcatheter mitral valve repair. Catheterization and Cardiovascular Interventions, 2021, 97, E569-E579.	1.7	6
112	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. European Journal of Preventive Cardiology, 2021, 28, 33-43.	1.8	33
113	Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy. European Journal of Heart Failure, 2021, 23, 384-392.	7.1	19
114	REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e61-e63.	3.0	23
115	Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent. American Heart Journal, 2021, 231, 147-156.	2.7	21
116	Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension. American Journal of Medicine, 2021, 134, e252-e263.	1.5	14
117	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine, 2021, 384, 117-128.	27.0	1,080
118	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 2021, 384, 129-139.	27.0	662
119	Linear and Nonlinear Mendelian Randomization Analyses of the Association Between Diastolic Blood Pressure and Cardiovascular Events. Circulation, 2021, 143, 895-906.	1.6	73
120	Underdiagnosis of Isolated Systolic and Isolated Diastolic Hypertension. American Journal of Cardiology, 2021, 141, 56-61.	1.6	3
121	Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. Journal of the American College of Cardiology, 2021, 77, 511-525.	2.8	11
122	Increased Prevalence of Myocardial Injury in Patients with SARS-CoV-2 Viremia. American Journal of Medicine, 2021, 134, 542-546.	1.5	17
123	Coronary Artery Calcium to Improve the Efficiency of Randomized Controlled Trials in Primary Cardiovascular Prevention. JACC: Cardiovascular Imaging, 2021, 14, 1005-1016.	5.3	18
124	Meta-Analysis of Transradial vs Transfemoral Access for Percutaneous Coronary Intervention in Patients With ST Elevation Myocardial Infarction. American Journal of Cardiology, 2021, 141, 23-30.	1.6	13
125	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation, 2021, 143, 470-478.	1.6	32
126	The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study. European Heart Journal, 2021, 42, 1728-1738.	2.2	53

#	ARTICLE	IF	CITATIONS
127	The Future of Aspirin Therapy in Cardiovascular Disease. American Journal of Cardiology, 2021, 144, S40-S47.	1.6	1
128	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2021, 42, 1289-1367.	2.2	3,048
129	Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System. Cardiovascular Drugs and Therapy, 2021, 35, 533-538.	2.6	1
130	Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. Future Cardiology, 2021, 17, 155-174.	1.2	14
131	Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from <scp>DECLARE–TIMI</scp> 58. Diabetes, Obesity and Metabolism, 2021, 23, 29-38.	4.4	28
132	Intensive blood pressure control appears to be effective and safe in patients with peripheral artery disease: the Systolic Blood Pressure Intervention Trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e38-e40.	3.0	3
133	Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2021, 325, 39.	7.4	65
134	Ultrasound-based internal carotid artery plaque characterization using deep learning paradigm on a supercomputer: a cardiovascular disease/stroke risk assessment system. International Journal of Cardiovascular Imaging, 2021, 37, 1511-1528.	1.5	34
135	The cost–effectiveness of dapagliflozin in treating high–risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE–TIMI 58 trial. Diabetes, Obesity and Metabolism, 2021, 23, 1020-1029.	4.4	19
136	Clinical Characteristics and Outcomes Associated With Oral Anticoagulant Use Among Patients Hospitalized With Intracerebral Hemorrhage. JAMA Network Open, 2021, 4, e2037438.	5.9	21
137	Effect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: a propensity score matching analysis. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 829-839.	1.0	34
138	The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. Diabetologia, 2021, 64, 1226-1234.	6.3	15
139	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. Circulation, 2021, 143, 685-695.	1.6	22
140	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circulation Genomic and Precision Medicine, 2021, 14, e003006.	3.6	6
141	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. Circulation, 2021, 143, 583-596.	1.6	119
142	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long–Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. Journal of the American Heart Association, 2021, 10, e017008.	3.7	17
143	Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS): a double-blind randomised placebo-controlled crossover trial. Diabetology and Metabolic Syndrome, 2021, 13, 17.	2.7	2
144	Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors. Stroke and Vascular Neurology, 2021, 6, 384-394.	3.3	3

#	ARTICLE	IF	CITATIONS
145	Letter by Angiolillo et al Regarding Article, “Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial” Circulation, 2021, 143, e795-e796.	1.6	1
146	Reoperative Mitral Surgery Versus Transcatheter Mitral Valve Replacement: A Systematic Review. Journal of the American Heart Association, 2021, 10, e019854.	3.7	24
147	The Emerging Role of Coronary Computed Tomography Angiography in Stable Angina With ISCHEMIA. JACC: Cardiovascular Imaging, 2021, 14, 1394-1397.	5.3	0
148	Intermediate-Term Outcomes of Endoscopic or Open Vein Harvesting for Coronary Artery Bypass Grafting. JAMA Network Open, 2021, 4, e211439.	5.9	21
149	Cardiovascular disease and stroke risk assessment in patients with chronic kidney disease using integration of estimated glomerular filtration rate, ultrasonic image phenotypes, and artificial intelligence: a narrative review. International Angiology, 2021, 40, 150-164.	0.9	15
150	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. Diabetes Care, 2021, 44, 1219-1227.	8.6	19
151	Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Diabetes Care, 2021, 44, 1159-1167.	8.6	25
152	Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol. Circulation, 2021, 143, 1109-1122.	1.6	46
153	Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies. Journal of Thrombosis and Thrombolysis, 2021, 52, 419-428.	2.1	2
154	Abstract P384: Outcomes of Endovascular Therapy in Patients With Pre-Stroke Mobility Impairment. Stroke, 2021, 52, .	2.0	0
155	The association between coronary graft patency and clinical status in patients with coronary artery disease. European Heart Journal, 2021, 42, 1433-1441.	2.2	32
156	Life and limb protection with dual anti-thrombotic pathway inhibition: COMPASS ushers in a new day in atherothrombotic risk reduction. Med, 2021, 2, 233-242.	4.4	1
157	Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA. European Heart Journal, 2021, 42, 1019-1034.	2.2	45
158	Crossover in COAPT. Journal of the American College of Cardiology, 2021, 77, 1041-1043.	2.8	1
159	To stent or not to stent? Treating angina after ISCHEMIA—the impact of the ISCHEMIA trial on the indications for angiography and revascularization in patients with stable coronary artery disease. European Heart Journal, 2021, 42, 1389-1393.	2.2	1
160	Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk. JAMA - Journal of the American Medical Association, 2021, 325, 1332.	7.4	9
161	Does SGLT1 Inhibition Add Benefit to SGLT2 Inhibition in Type 2 Diabetes?. Circulation, 2021, 144, 4-6.	1.6	24
162	To stent or not to stent? Treating angina after ISCHEMIA—introduction. European Heart Journal, 2021, 42, 1387-1400.	2.2	3

#	ARTICLE	IF	CITATIONS
163	Transmitting Device Identifiers of Implants From the Point of Care to Insurers: A Demonstration Project. <i>Journal of Patient Safety</i> , 2021, 17, 223-230.	1.7	6
164	Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 768-780.	2.9	5
165	The EVAPORATE trial provides important mechanistic data on plaque characteristics that have relevance to the REDUCE-IT results and clinical use of icosapent ethyl. <i>European Heart Journal</i> , 2021, 42, 3025-3026.	2.2	5
166	The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL) Tj ETQq0 0 0 ggBT /Overlock 10 T Cardiology, 2021, 44, 1002-1010.	1.8	2
167	Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2366-2377.	2.8	13
168	Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE). <i>American Heart Journal</i> , 2021, 235, 54-64.	2.7	11
169	Device-Related Thrombus After Left Atrial Appendage Closure: Data on Thrombus Characteristics, Treatment Strategies, and Clinical Outcomes From the EUROCDRT-Registry. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010195.	3.9	46
170	Patient perspectives on the need for implanted device information: Implications for a post-procedural communication framework. <i>Health Expectations</i> , 2021, 24, 1391-1402.	2.6	6
171	Impella in Cardiogenic Shock: Is it Time to Hit the Break?. <i>Shock</i> , 2021, 55, 693-694.	2.1	4
172	Variation in treatment strategy for NSTEMI: A complex phenomenon. <i>International Journal of Cardiology</i> , 2021, 331, 14-16.	1.7	1
173	Association between COVID-19 outcomes and mask mandates, adherence, and attitudes. <i>PLoS ONE</i> , 2021, 16, e0252315.	2.5	63
174	Mapping and quantification of the twitter footprint of cardiologists. <i>European Heart Journal Digital Health</i> , 2021, 2, 374-378.	1.7	5
175	SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2021, 36, 100933.	7.1	67
176	Patient-reported Outcomes After Metabolic Surgery Versus Medical Therapy for Diabetes. <i>Annals of Surgery</i> , 2021, 274, 524-532.	4.2	18
177	Accuracy of ICD-10 Diagnostic Codes to Identify COVID-19 Among Hospitalized Patients. <i>Journal of General Internal Medicine</i> , 2021, 36, 2532-2535.	2.6	29
178	Characteristics of Randomized Clinical Trials in Surgery From 2008 to 2020. <i>JAMA Network Open</i> , 2021, 4, e2114494.	5.9	42
179	Association Between Omega-3 Fatty Acid Levels and Risk for Incident Major Bleeding Events and Atrial Fibrillation: MESA. <i>Journal of the American Heart Association</i> , 2021, 10, e021431.	3.7	8
180	Long-Term Outcomes Following Myocardial Infarction in Young Adult Survivors of Hodgkin Lymphoma. <i>JACC: CardioOncology</i> , 2021, 3, 319-321.	4.0	2

#	ARTICLE	IF	CITATIONS
181	Hospital Readmission in Patients With Spontaneous Coronary Artery Dissection. American Journal of Cardiology, 2021, 151, 39-44.	1.6	7
182	Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives. Journal of the American Heart Association, 2021, 10, e022125.	3.7	31
183	The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care, 2021, 44, 1805-1815.	8.6	49
184	Improving Terminology to Describe Coronary Artery Procedures. Journal of the American College of Cardiology, 2021, 78, 180-188.	2.8	16
185	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. Journal of the American College of Cardiology, 2021, 78, 14-23.	2.8	31
186	Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes. JAMA Cardiology, 2021, 6, 801.	6.1	26
187	Reconfiguring the Cardiovascular Clinical Trial Enterprise in the United States. JAMA Network Open, 2021, 4, e2118176.	5.9	3
188	Generalizability of DAPA-CKD to the United States. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007875.	2.2	7
189	Impact of Chronic Kidney Disease on Revascularization and Outcomes in Patients with ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2021, 150, 15-23.	1.6	5
190	Effect of Continuous Electrocardiogram Monitoring on Detection of Undiagnosed Atrial Fibrillation After Hospitalization for Cardiac Surgery. JAMA Network Open, 2021, 4, e2121867.	5.9	24
191	New Antidiabetes Medications and Their Cardiovascular and Renal Benefits. Cardiology Clinics, 2021, 39, 335-351.	2.2	10
192	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. Annals of Internal Medicine, 2021, 174, 1065-1072.	3.9	32
193	Same-Day Discharge After Elective PCI. JACC: Cardiovascular Interventions, 2021, 14, 1667-1669.	2.9	2
194	The role of eicosapentaenoic acid in reducing important cardiovascular events, including coronary revascularization. Progress in Cardiovascular Diseases, 2021, 69, 3-10.	3.1	15
195	Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. Circulation, 2021, 144, 1295-1307.	1.6	75
196	Natural language processing for the assessment of cardiovascular disease comorbidities: The <sc>cardioCanary</sc> comorbidity project. Clinical Cardiology, 2021, 44, 1296-1304.	1.8	12
197	Trends in Cerebral Embolic Protection Device Use and Association With Stroke Following Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2021, 152, 106-112.	1.6	9
198	What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry. Journal of the American Heart Association, 2021, 10, e020893.	3.7	9

#	ARTICLE	IF	CITATIONS
199	Patient-specific computational simulation of coronary artery bifurcation stenting. Scientific Reports, 2021, 11, 16486.	3.3	13
200	Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. EClinicalMedicine, 2021, 38, 100997.	7.1	121
201	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. Journal of the American College of Cardiology, 2021, 78, 421-433.	2.8	58
202	Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. International Journal of Cardiology, 2021, 337, 1-8.	1.7	6
203	Role of Cardiac CT in Pre-Procedure Planning for Transcatheter Mitral Valve Replacement. JACC: Cardiovascular Imaging, 2021, 14, 1571-1580.	5.3	16
204	Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction. JAMA Cardiology, 2021, 6, 880.	6.1	36
205	Meta-Analysis of Contemporary Trials of Omega-3 Fatty Acids Containing Both Eicosapentaenoic and Docosahexaenoic Acids. EClinicalMedicine, 2021, 39, 101110.	7.1	5
206	Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US. JAMA Cardiology, 2021, 6, 1060.	6.1	86
207	Is There an Optimal Antiplatelet Strategy after Gastrointestinal Bleeding in Patients with Coronary Artery Disease?. Cardiology, 2021, 146, 668-677.	1.4	0
208	Long-term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. Journal of the American Heart Association, 2021, 10, e020446.	3.7	7
209	Efficacy of Acclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial. Advances in Therapy, 2021, 38, 5381-5397.	2.9	0
210	The Impact of American College of Cardiology Chest Pain Center Accreditation on Guideline Recommended Acute Myocardial Infarction Management. Critical Pathways in Cardiology, 2021, Publish Ahead of Print, 173-178.	0.5	0
211	Intracranial Hemorrhage During Dual Antiplatelet Therapy. Journal of the American College of Cardiology, 2021, 78, 1372-1384.	2.8	17
212	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Diabetes Care, 2021, 44, 2573-2581.	8.6	13
213	Adaptive Trials in Cardiology: Some Considerations and Examples. Canadian Journal of Cardiology, 2021, 37, 1428-1437.	1.7	2
214	Improving Communication of Incidental Imaging Findings. Mayo Clinic Proceedings, 2021, 96, 2753-2756.	3.0	0
215	Outcomes of Endovascular Therapy in Patients With Prestroke Mobility Impairment. Stroke, 2021, 52, e725-e728.	2.0	0
216	A randomized trial of icosapent ethyl in ambulatory patients with COVID-19. IScience, 2021, 24, 103040.	4.1	19

#	ARTICLE	IF	CITATIONS
217	A novel technique for invasive aortic valve pressure gradient measurement using a 6â€‰Fr Swan-Ganz catheter: a case series. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab383.	0.6	0
218	3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1870-1883.	2.9	56
219	Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States. <i>Progress in Cardiovascular Diseases</i> , 2021, 68, 97-98.	3.1	6
220	Meta-Analysis of Transradial Versus Transfemoral Access for Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease. <i>American Journal of Cardiology</i> , 2021, 157, 8-14.	1.6	6
221	Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry. <i>International Journal of Cardiology</i> , 2021, 340, 96-104.	1.7	9
222	Acute Myocardial Infarction Within 24 Hours After COVID-19 Vaccination. <i>American Journal of Cardiology</i> , 2021, 156, 129-131.	1.6	33
223	Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2021, 173, 102337.	2.2	32
224	Safety and Feasibility of Same-Day Discharge After Left Atrial Appendage Closure With the WATCHMAN Device. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009669.	3.9	28
225	Transcatheter aortic valve replacement same-day discharge for selected patients: a case series. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytaa556.	0.6	15
226	EPA and DHA containing phospholipids have contrasting effects on membrane structure. <i>Journal of Lipid Research</i> , 2021, 62, 100106.	4.2	28
227	Generalizability of Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial in patients with a history of coronary artery bypass graft surgery. <i>Current Opinion in Cardiology</i> , 2021, 36, 172-178.	1.8	10
228	The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl. <i>European Heart Journal</i> , 2021, 42, 4865-4866.	2.2	12
229	Women and Diabetes: Preventing Heart Disease in a New Era of Therapies. <i>European Cardiology Review</i> , 2021, 16, e40.	2.2	9
230	Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers. <i>Respiratory Research</i> , 2021, 22, 272.	3.6	1
231	Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1550-1563.	2.8	16
232	Time to Remove the Left Atrial Appendage at Surgery: LAAOS III in Perspective. <i>Circulation</i> , 2021, 144, 1088-1090.	1.6	4
233	Same-day discharge after transcatheter mitral valve repair using MitraClip in a tertiary community hospital: a case series. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab397.	0.6	7
234	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1635-1654.	2.8	42

#	ARTICLE	IF	CITATIONS
235	Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. Journal of the American College of Cardiology, 2021, 78, 1525-1537.	2.8	25
236	Serum Potassium and Mortality in High-Risk Patients: SPRINT. Hypertension, 2021, 78, 1586-1594.	2.7	3
237	Emerging Transcatheter Options for Tricuspid Regurgitation. Methodist DeBakey Cardiovascular Journal, 2021, 13, 120.	1.0	9
238	Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. Circulation, 2021, 144, 1845-1855.	1.6	39
239	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2021, 144, e368-e454.	1.6	319
240	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. Journal of the American College of Cardiology, 2021, 78, e187-e285.	2.8	336
241	Innovation in intervention. Progress in Cardiovascular Diseases, 2021, 69, 1-2.	3.1	4
242	Antithrombotic Therapy for Stroke Prevention in Patients With Ischemic Stroke With Aspirin Treatment Failure. Stroke, 2021, 52, e777-e781.	2.0	2
243	Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. Circulation, 2021, 144, 1750-1759.	1.6	36
244	EMPEROR-Preserved: A promise fulfilled. Cell Metabolism, 2021, 33, 2099-2103.	16.2	8
245	SGLT-2 inhibitors in heart failure: Time for broader eligibility and earlier initiation. Cleveland Clinic Journal of Medicine, 2021, 88, 601-606.	1.3	2
246	Outcomes of Medicare beneficiaries hospitalised with transient ischaemic attack and stratification using the ABCD ² score. Stroke and Vascular Neurology, 2021, 6, 314-318.	3.3	1
247	Dual pathway inhibition in atherothrombosis prevention: yes, now we can!. Minerva Cardiology and Angiology, 2021, , .	0.7	2
248	Recruitment Practices in Multicenter Randomized Clinical Trials: Time for a Relook. Journal of the American Heart Association, 2021, 10, e023673.	3.7	1
249	Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI. Journal of the American College of Cardiology, 2021, 78, 2060-2072.	2.8	39
250	Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial. Circulation: Cardiovascular Interventions, 2021, , CIRCINTERVENTIONS120011035.	3.9	2
251	Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis. JACC: CardioOncology, 2021, 3, 619-634.	4.0	49
252	Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial). PLoS ONE, 2021, 16, e0259372.	2.5	6

#	ARTICLE	IF	CITATIONS
253	Impact of sex on outcomes of percutaneous coronary intervention for chronic total occlusion: A meta-analysis. Catheterization and Cardiovascular Interventions, 2021, , .	1.7	4
254	Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 774418.	2.4	23
255	Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19. JAMA Network Open, 2021, 4, e2141328.	5.9	30
256	Saphenous Vein Graft Failure: From Pathophysiology to Prevention and Treatment Strategies. Circulation, 2021, 144, 728-745.	1.6	75
257	Abstract 10632: Variation in the Association Between Beta Blocker and/or Rasi Use After Discharge and Outcomes in Hfref by Age. Circulation, 2021, 144, .	1.6	0
258	Abstract 10868: Risk Factors and Long-Term Outcomes of Cardiogenic Shock in Young Patients with Myocardial Infarction - The Mass General Brigham Young-MI Registry. Circulation, 2021, 144, .	1.6	0
259	Left circumflex artery injury following surgical mitral valve replacement: a case report. European Heart Journal - Case Reports, 2021, 5, ytab464.	0.6	5
260	Guideline based eligibility for primary prevention statin therapy â€“ Insights from the North India ST-elevation myocardial infarction registry (NORIN-STEMI). Journal of Clinical Lipidology, 2021, , .	1.5	4
261	Passive longitudinal weight and cardiopulmonary monitoring in the home bed. Scientific Reports, 2021, 11, 24376.	3.3	5
262	Race and Ethnicity Considerations in Patients With Coronary Artery Disease and Stroke. Journal of the American College of Cardiology, 2021, 78, 2483-2492.	2.8	33
263	Cardiovascular Safety Assessment in Cancer Drug Development. Journal of the American Heart Association, 2021, 10, e024033.	3.7	5
264	Abstract 9758: Estimating Cardiovascular and Limb Benefits of Combined Contemporary Risk Reduction Therapies in Patients with Symptomatic Peripheral Artery Disease: An Analysis of Randomized Controlled Trials. Circulation, 2021, 144, .	1.6	0
265	Meta-analysis of optimal timing of coronary intervention in non-ST-elevation acute coronary syndrome. Catheterization and Cardiovascular Interventions, 2020, 95, 185-193.	1.7	13
266	Coronary Embolism: A Systematic Review. Cardiovascular Revascularization Medicine, 2020, 21, 367-374.	0.8	27
267	Interventions for Secondary Mitral Regurgitation in Patients With Heart Failure: A Network Meta-Analysis of Randomized Controlled Comparisons of Surgery, Medical Therapy and Transcatheter Intervention. Cardiovascular Revascularization Medicine, 2020, 21, 155-163.	0.8	7
268	Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 356-363.	3.0	19
269	A LEADER in the management of type 2 diabetes and cardiorenal disease. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 978-984.	0.8	2
270	Aortic Valve Replacement in Bioprosthetic Failure: Insights From The Society of Thoracic Surgeons National Database. Annals of Thoracic Surgery, 2020, 110, 1637-1642.	1.3	17

#	ARTICLE	IF	CITATIONS
271	On the Pearls and Perils of Sub-Subspecialization. American Journal of Medicine, 2020, 133, 158-159.	1.5	6
272	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. European Journal of Preventive Cardiology, 2020, 27, 296-307.	1.8	28
273	Meta-Analysis of Transcatheter Aortic Valve Replacement in Low-Risk Patients. American Journal of Medicine, 2020, 133, e38-e41.	1.5	9
274	Longitudinal trajectories of hospital performance across targeted cardiovascular conditions in the USA. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 62-71.	4.0	3
275	Risk Factors and Outcomes of Very Young Adults Who Experience Myocardial Infarction: The Partners YOUNG-MI Registry. American Journal of Medicine, 2020, 133, 605-612.e1.	1.5	73
276	REDUCE-IT USA. Circulation, 2020, 141, 367-375.	1.6	104
277	Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. American Heart Journal, 2020, 219, 70-77.	2.7	18
278	Incidental Imaging Findings in Clinical Trials. JAMA - Journal of the American Medical Association, 2020, 323, 603.	7.4	9
279	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. Journal of the American College of Cardiology, 2020, 75, 133-144.	2.8	296
280	Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2020, 75, 238-240.	2.8	2
281	Comparison of Incidence and Outcomes of Cardiogenic Shock Complicating Posterior (Inferior) Versus Anterior ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2020, 125, 1013-1019.	1.6	3
282	Safety and Outcomes of Intravenous tPA in Acute Ischemic Stroke Patients With Prior Stroke Within 3 Months. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006031.	2.2	12
283	An Optimized Approach for Transfemoral Transcatheter Aortic Valve Implantation: A Comprehensive Review and Current Evidence. Cardiovascular Revascularization Medicine, 2020, 21, 1034-1040.	0.8	3
284	Strict Versus Lenient Versus Poor Rate Control Among Patients With Atrial Fibrillation and Heart Failure (from the Get With The Guidelines "Heart Failure Program). American Journal of Cardiology, 2020, 125, 894-900.	1.6	15
285	Does Interleukin-17A Blockade Have a Potential Clinical Role to Reduce Cardiovascular Risk in Psoriasis?. Canadian Journal of Cardiology, 2020, 36, 24-26.	1.7	1
286	Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. European Heart Journal, 2020, 41, 2304-2312.	2.2	54
287	Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. European Heart Journal, 2020, 41, 1625-1632.	2.2	27
288	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. European Heart Journal, 2020, 41, 2248-2258.	2.2	51

#	ARTICLE	IF	CITATIONS
289	Palliative Care Use in Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology, 2020, 75, 113-117.	2.8	16
290	Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. Diabetes Care, 2020, 43, 468-475.	8.6	72
291	Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography. Cardiovascular Research, 2020, 116, 479-482.	3.8	38
292	Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Tj ETQq 0.0 rgBT/O	1.6	13
293	Antithrombotic therapy for chronic coronary syndrome and atrial fibrillation: less might be more. Journal of Thrombosis and Thrombolysis, 2020, 49, 321-324.	2.1	3
294	Minding the gaps in post-myocardial infarction mortality between Sweden and the UK. Cardiovascular Research, 2020, 116, 9-11.	3.8	0
295	Recurrent spontaneous coronary artery dissection in the United States. International Journal of Cardiology, 2020, 301, 34-37.	1.7	19
296	Randomized, Controlled Trial Comparing Mitral Valve Repair With Leaflet Resection Versus Leaflet Preservation on Functional Mitral Stenosis. Circulation, 2020, 142, 1342-1350.	1.6	25
297	Incidence, Characteristics, Predictors, and Outcomes of Surgical Explantation After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2020, 76, 1848-1859.	2.8	56
298	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. European Heart Journal, 2020, 41, 4245-4255.	2.2	117
299	Secondary prevention of cardiovascular diseases in India: Findings from registries and large cohorts. Indian Heart Journal, 2020, 72, 337-344.	0.5	3
300	Effects of the COVID-19 Pandemic on Active Non-COVID Clinical Trials. Journal of the American College of Cardiology, 2020, 76, 1605-1606.	2.8	17
301	Reply. JACC: Cardiovascular Interventions, 2020, 13, 2309-2310.	2.9	0
302	A questionnaire survey for improving awareness of rheumatic heart disease among school-aged children in India. Indian Heart Journal, 2020, 72, 410-415.	0.5	3
303	Overall and Cause-Specific Mortality in Randomized Clinical Trials Comparing Percutaneous Interventions With Coronary Bypass Surgery. JAMA Internal Medicine, 2020, 180, 1638.	5.1	72
304	Women who experience a myocardial infarction at a young age have worse outcomes compared with men: the Mass General Brigham YOUNG-MI registry. European Heart Journal, 2020, 41, 4127-4137.	2.2	77
305	Association Between Universal Masking in a Health Care System and SARS-CoV-2 Positivity Among Health Care Workers. JAMA - Journal of the American Medical Association, 2020, 324, 703.	7.4	269
306	Quantifying the Impact of Care Fragmentation on Outcomes After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2020, 128, 113-119.	1.6	0

#	ARTICLE	IF	CITATIONS
307	Trends in Costs and Risk Factors of 30-Day Readmissions for Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2020, 137, 89-96.	1.6	5
308	Addressing bias: artificial intelligence in cardiovascular medicine. The Lancet Digital Health, 2020, 2, e635-e636.	12.3	48
309	U.S. Prevalence of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 Inhibitor Therapy. Journal of the American College of Cardiology, 2020, 76, 2907-2910.	2.8	5
310	A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1517-1528.	0.9	2
311	Cardiopulmonary Impact of Particulate Air Pollution in High-Risk Populations. Journal of the American College of Cardiology, 2020, 76, 2878-2894.	2.8	68
312	Three-Year Outcomes of Bariatric Surgery in Patients With Obesity and Hypertension. Annals of Internal Medicine, 2020, 173, 685-693.	3.9	55
313	Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. JAMA Cardiology, 2020, 5, 1255.	6.1	27
314	No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials. JACC: Cardiovascular Interventions, 2020, 13, 1012-1014.	2.9	5
315	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation, 2020, 142, 734-747.	1.6	44
316	Infective Endocarditis After Surgical and Transcatheter Aortic Valve Replacement: A State of the Art Review. Journal of the American Heart Association, 2020, 9, e017347.	3.7	38
317	Self-employment and cardiovascular risk in the US general population. International Journal of Cardiology: Hypertension, 2020, 6, 100035.	2.2	5
318	The Landscape of Cardiovascular Clinical Trials in the United States Initiated Before and During COVID-19. Journal of the American Heart Association, 2020, 9, e018274.	3.7	14
319	Federal judge invalidates icosapent ethyl patents “but on the basis of a common statistical mistake. Nature Biotechnology, 2020, 38, 939-941.	17.5	2
320	Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 2020, 9, e017212.	3.7	52
321	Intensive vs. standard blood pressure control and vascular procedures: insights from the Systolic Blood Pressure Intervention Trial (SPRINT). European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 7, e35-e37.	3.0	1
322	Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Diabetes, Obesity and Metabolism, 2020, 22, 2487-2492.	4.4	31
323	Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents. Circulation, 2020, 142, 1425-1436.	1.6	109
324	Randomized Trials Versus Common Sense and Clinical Observation. Journal of the American College of Cardiology, 2020, 76, 580-589.	2.8	50

#	ARTICLE	IF	CITATIONS
325	Differential effect of ticagrelor on irreversible harms in diabetes – Authors' reply. Lancet, The, 2020, 396, 93-94.	13.7	0
326	A Revolution in Omega-3 Fatty Acid Research. Journal of the American College of Cardiology, 2020, 76, 2098-2101.	2.8	21
327	The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction. Current Diabetes Reports, 2020, 20, 65.	4.2	18
328	Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside. European Heart Journal Supplements, 2020, 22, J1-J2.	0.1	8
329	Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. European Heart Journal, 2020, 41, 3925-3932.	2.2	257
330	Quality of Care and Outcomes Among Medicare Advantage vs Fee-for-Service Medicare Patients Hospitalized With Heart Failure. JAMA Cardiology, 2020, 5, 1349.	6.1	13
331	The COVID-19 pandemic: a catalyst to improve clinical trials. Nature Reviews Cardiology, 2020, 17, 673-675.	13.7	37
332	Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006582.	2.2	5
333	Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome. Circulation, 2020, 142, 1579-1590.	1.6	28
334	Trends in Reperfusion Therapy for In-Hospital Ischemic Stroke in the Endovascular Therapy Era. JAMA Neurology, 2020, 77, 1486.	9.0	37
335	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. Stroke, 2020, 51, 2901-2909.	2.0	15
336	Artificial intelligence in medical imaging: switching from radiographic pathological data to clinically meaningful endpoints. The Lancet Digital Health, 2020, 2, e486-e488.	12.3	128
337	Revascularization Practices and Outcomes in Patients With Multivessel Coronary Artery Disease Who Presented With Acute Myocardial Infarction and Cardiogenic Shock in the US, 2009-2018. JAMA Internal Medicine, 2020, 180, 1317.	5.1	21
338	“Cholesterol-Years” for ASCVD Risk Prediction and Treatment. Journal of the American College of Cardiology, 2020, 76, 1517-1520.	2.8	22
339	Trial Design Principles for Patients at High-Bleeding Risk Undergoing PCI. Journal of the American College of Cardiology, 2020, 76, 1468-1483.	2.8	35
340	Long-term predictive value of stroke volume index obtained from right heart catheterization: Insights from the veterans affairs clinical assessment, reporting, and tracking program. Clinical Cardiology, 2020, 43, 1126-1132.	1.8	4
341	Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry. Clinical Cardiology, 2020, 43, 1209-1215.	1.8	7
342	Genetic Variation in Cardiometabolic Traits and Medication Targets and the Risk of Hypertensive Disorders of Pregnancy. Circulation, 2020, 142, 711-713.	1.6	27

#	ARTICLE	IF	CITATIONS
343	Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. <i>European Heart Journal</i> , 2020, 41, 4114-4123.	2.2	35
344	Antiplatelet patterns and outcomes in patients with atrial fibrillation not prescribed an anticoagulant after stroke. <i>International Journal of Cardiology</i> , 2020, 321, 88-94.	1.7	3
345	Effects of Epeleuton, a Novel Synthetic Second-Generation ω 3 Fatty Acid, on Non-Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers. <i>Journal of the American Heart Association</i> , 2020, 9, e016334.	3.7	17
346	Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST-WHF in perspective. <i>ESC Heart Failure</i> , 2020, 7, 3261-3267.	3.1	16
347	Applying to Medical School in the COVID-19 Era. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2317-2319.	3.0	4
348	Prognostic implications of left ventricular hypertrophy diagnosed on electrocardiogram vs echocardiography. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1647-1658.	2.0	15
349	New Decade, New FDA Guidance for Diabetes Drug Development. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2522-2526.	2.8	12
350	Regulation of Cardiovascular Therapies During the COVID-19 Public Health Emergency. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2517-2521.	2.8	10
351	Twitter-based learning for continuing medical education?. <i>European Heart Journal</i> , 2020, 41, 4376-4379.	2.2	40
352	Closing Gaps in Essential Chest Pain Care Through Accreditation. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2478-2482.	2.8	9
353	Diabetes Is Associated With Worse Long-term Outcomes in Young Adults After Myocardial Infarction: The Partners YOUNG-MI Registry. <i>Diabetes Care</i> , 2020, 43, 1843-1850.	8.6	27
354	The Reply. <i>American Journal of Medicine</i> , 2020, 133, e164-e165.	1.5	0
355	The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the <sc>LEADER</sc> and <sc>SUSTAIN</sc> 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1690-1695.	4.4	19
356	Rural-Urban Differences in Cardiovascular Mortality in the US, 1999-2017. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1852.	7.4	94
357	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2297-2308.	2.8	48
358	Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. <i>American Journal of Medicine</i> , 2020, 133, 1302-1312.	1.5	1
359	Association Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients With Acute Ischemic Stroke. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2170.	7.4	92
360	Long-Term Outcomes With Drug-Eluting Stents or Coronary Artery Bypass Surgery for Unprotected Left Main Coronary Disease: A Meta-Analysis and Trial Sequential Analysis of Randomized Trials. <i>American Journal of Cardiology</i> , 2020, 126, 111-112.	1.6	2

#	ARTICLE	IF	CITATIONS
361	Association Between the Framingham Risk Score and Carotid Artery Intima-Media Thickness in Patients With Human Immunodeficiency Virus. <i>American Journal of Cardiology</i> , 2020, 127, 156-162.	1.6	4
362	Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic. <i>Journal of the American College of Cardiology</i> , 2020, 76, 280-288.	2.8	259
363	Response by Bhatt et al to Letter Regarding Article, "REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States", <i>Circulation</i> , 2020, 141, e834-e835.	1.6	3
364	The Consequences of the COVID-19 Pandemic on Non-COVID-19 Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2020, 76, 342-345.	2.8	43
365	Necessity of 45-Day Transesophageal Echocardiography After the WATCHMAN Procedure Amid the COVID-19 Pandemic. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2461-2462.	5.3	7
366	Complete revascularization for patients with multivessel coronary artery disease and ST-segment elevation myocardial infarction after the COMPLETE trial: A meta-analysis of randomized controlled trials. <i>IJC Heart and Vasculature</i> , 2020, 29, 100549.	1.1	3
367	Association of high-density lipoprotein levels with baseline coronary plaque volumes by coronary CTA in the EVAPORATE trial. <i>Atherosclerosis</i> , 2020, 305, 34-41.	0.8	7
368	Influence of Influenza Infection on In-Hospital Acute Myocardial Infarction Outcomes. <i>American Journal of Cardiology</i> , 2020, 130, 7-14.	1.6	13
369	Self-treatment for acute coronary syndrome: why not?. <i>European Heart Journal</i> , 2020, 41, 2144-2145.	2.2	7
370	Sex Differences in Case Fatality Rate of COVID-19: Insights From a Multinational Registry. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1613-1620.	3.0	107
371	Special Article - Acute myocardial injury in patients hospitalized with COVID-19 infection: A review. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 682-689.	3.1	221
372	Periodontal Inflammation and the Risk of Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2020, 22, 28.	4.8	61
373	Early Post-Percutaneous Coronary Intervention Chest Pain: A Nationwide Survey on Interventional Cardiologists' Perspective. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1517-1522.	0.8	4
374	Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial. <i>Drugs</i> , 2020, 80, 995-1005.	10.9	8
375	The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 895-897.	0.7	22
376	Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). <i>Circulation</i> , 2020, 141, 1141-1151.	1.6	39
377	Contrast-Associated Acute Kidney Injury And Serious Adverse Outcomes Following Angiography. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1311-1320.	2.8	57
378	Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 1135-1147.	2.4	240

#	ARTICLE	IF	CITATIONS
379	Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials. <i>JAMA Cardiology</i> , 2020, 5, 714.	6.1	76
380	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1841-1854.	1.6	96
381	Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome. <i>Circulation</i> , 2020, 141, 1608-1617.	1.6	104
382	Looking into the next decade of antithrombotic therapy for patients with atrial fibrillation and percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 522-526.	2.1	0
383	Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trial. <i>Lancet, The</i> , 2020, 396, 669-683.	13.7	76
384	Pregnancy as a Cardiac Stress Test. <i>Journal of the American College of Cardiology</i> , 2020, 76, 68-71.	2.8	10
385	Association of Smoking Cessation and Survival Among Young Adults With Myocardial Infarction in the Partners YOUNG-MI Registry. <i>JAMA Network Open</i> , 2020, 3, e209649.	5.9	38
386	Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2020, 195, 128-135.	1.7	3
387	Prevalence and Outcomes of Acute Ischemic Stroke Among Patients ≥50 Years of Age With Laboratory Confirmed COVID-19 Infection. <i>American Journal of Cardiology</i> , 2020, 130, 169-170.	1.6	36
388	Management of acute myocardial injury in patients with confirmed or suspected COVID-19. <i>Atherosclerosis</i> , 2020, 305, 58-60.	0.8	2
389	Multivessel Versus Culprit-Only Revascularization in STEMI and Multivessel Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1571-1582.	2.9	33
390	Meta-analysis of bivalirudin versus heparin in transradial coronary interventions. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1240-1248.	1.7	8
391	Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2020, 5, 582.	6.1	71
392	Performance in Federal Value-Based Programs of Hospitals Recognized by the American Heart Association and American College of Cardiology for High-Quality Heart Failure and Acute Myocardial Infarction Care. <i>JAMA Cardiology</i> , 2020, 5, 515.	6.1	15
393	Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 337-343.	2.1	11
394	Population-based long-term outcomes of open versus endovascular aortic repair of ruptured abdominal aortic aneurysms. <i>Journal of Vascular Surgery</i> , 2020, 71, 1867-1878.e8.	1.1	15
395	Continued Evolution of Renal Artery Denervation for Hypertension. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 485-487.	2.9	2
396	Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1122-1131.	4.4	16

#	ARTICLE	IF	CITATIONS
397	Cardiovascular Mortality After Type 1 and Type 2 Myocardial Infarction in Young Adults. Journal of the American College of Cardiology, 2020, 75, 1003-1013.	2.8	49
398	Running thin: implications of a heparin shortage. Lancet, The, 2020, 395, 534-536.	13.7	20
399	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nature Reviews Cardiology, 2020, 17, 242-257.	13.7	87
400	The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. Biochemical and Biophysical Research Communications, 2020, 524, 50-56.	2.1	69
401	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. Circulation, 2020, 141, 1227-1234.	1.6	241
402	Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY OUTCOMES. Journal of the American College of Cardiology, 2020, 75, 448-451.	2.8	6
403	Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk. Circulation, 2020, 141, 891-901.	1.6	28
404	Association of Outpatient Practice-Level Socioeconomic Disadvantage With Quality of Care and Outcomes Among Older Adults With Coronary Artery Disease. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e005977.	2.2	28
405	Performance of Hospitals When Assessing Disease-Based Mortality Compared With Procedural Mortality for Patients With Acute Myocardial Infarction. JAMA Cardiology, 2020, 5, 765.	6.1	10
406	Bariatric Surgery Improves HDL Function Examined by ApoA1 Exchange Rate and Cholesterol Efflux Capacity in Patients with Obesity and Type 2 Diabetes. Biomolecules, 2020, 10, 551.	4.0	27
407	Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. American Journal of Cardiology, 2020, 125, 1577-1581.	1.6	2
408	Characteristics, results, and reporting of contemporary surgical trials: A systematic review and analysis. International Journal of Surgery Protocols, 2020, 21, 1-4.	1.1	1
409	Selective Autoretroperfusion Provides Substantial Cardioprotection in Swine. JACC Basic To Translational Science, 2020, 5, 267-278.	4.1	1
410	Randomized Trials in Cardiac Surgery. Journal of the American College of Cardiology, 2020, 75, 1593-1604.	2.8	28
411	Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. Diabetes, Obesity and Metabolism, 2020, 22, 1357-1368.	4.4	26
412	Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer. JACC: CardioOncology, 2020, 2, 70-81.	4.0	30
413	Sleep Duration and Cardiovascular Health in a Representative Community Population (from NHANES,) Tj ETQq1 1 0,784314 rgBT /Overl	1.6	38
414	Prevalence of Multiplicity and Appropriate Adjustments Among Cardiovascular Randomized Clinical Trials Published in Major Medical Journals. JAMA Network Open, 2020, 3, e203082.	5.9	9

#	ARTICLE	IF	CITATIONS
415	Adherence to Guideline Medication Recommendations to Prevent Atherosclerotic Cardiovascular Disease Progression Among Adults With Prior Myocardial Infarction. JAMA Network Open, 2020, 3, e203032.	5.9	12
416	Clinical features and prognosis of patients with spontaneous coronary artery dissection. International Journal of Cardiology, 2020, 312, 33-36.	1.7	16
417	Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation, 2020, 141, e779-e806.	1.6	157
418	Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e008349.	3.9	15
419	Recovery of Left Ventricular Systolic Function and Clinical Outcomes in Young Adults With Myocardial Infarction. Journal of the American College of Cardiology, 2020, 75, 2804-2815.	2.8	30
420	Vascular Risk Reduction in Obesity through Reduced Granulocyte Burden and Improved Angiogenic Monocyte Content following Bariatric Surgery. Cell Reports Medicine, 2020, 1, 100018.	6.5	16
421	Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. European Heart Journal Supplements, 2020, 22, J34-J48.	0.1	68
422	Beyond cardiovascular medicine: potential future uses of icosapent ethyl. European Heart Journal Supplements, 2020, 22, J54-J64.	0.1	9
423	Abstract 16139: A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58. Circulation, 2020, 142, .	1.6	1
424	Target: Stroke Was Associated With Faster Intravenous Thrombolysis and Improved One-Year Outcomes for Acute Ischemic Stroke in Medicare Beneficiaries. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e007150.	2.2	8
425	Confounding Factors in Renal Denervation Trials. Hypertension, 2020, 76, 1410-1417.	2.7	33
426	Global perspective on carotid intima-media thickness and plaque: should the current measurement guidelines be revisited?. International Angiology, 2020, 38, 451-465.	0.9	39
427	Low-cost preventive screening using carotid ultrasound in patients with diabetes. Frontiers in Bioscience - Landmark, 2020, 25, 1132-1171.	3.0	29
428	Integration of cardiovascular risk assessment with COVID-19 using artificial intelligence. Reviews in Cardiovascular Medicine, 2020, 21, 541.	1.4	24
429	Baroreflex Activation Therapy for Resistant Hypertension and Heart Failure. US Cardiology Review, 2020, 13, 83-87.	0.5	2
430	Amyloidosis and 30-Day Outcomes Among Patients With Heart Failure. JACC: CardioOncology, 2020, 2, 710-718.	4.0	5
431	Abstract P108: Cardiovascular Health Awareness and the Effect of an Educational Intervention on School-aged Children in Calcutta, India. Circulation, 2020, 141, .	1.6	0
432	IgM Antibodies with atheroprotective properties in heart transplants are IgM anti- ϵ -phosphorylcholine. FASEB Journal, 2020, 34, 1-1.	0.5	0

#	ARTICLE	IF	CITATIONS
433	Abstract 14997: Icosapent Ethyl Reduces Ischemic Events in Patients With Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG. Circulation, 2020, 142, .	1.6	0
434	Abstract 13214: Underuse of Combination Pharmacotherapy for Management of Dyslipidemia versus Diabetes and Hypertension Among Patients With Atherosclerotic Cardiovascular Disease (ascvd): Insights From the Getting to an Improved Understanding of Low-density Lipoprotein-cholesterol and Dyslipidemia Management (gould) Registry. Circulation, 2020, 142, .	1.6	0
435	Abstract 13702: A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation, 2020, 142, .	1.6	0
436	Abstract 15913: Two-year Results of the Getting to an Improved Understanding of Low-density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) Registry of Patients With Atherosclerotic Cardiovascular Disease (ASCVD). Circulation, 2020, 142, .	1.6	0
437	Abstract 15091: Significant Reductions in Both Adjudicated and Investigator-Reported Ischemic Events in REDUCE-IT. Circulation, 2020, 142, .	1.6	0
438	Abstract 14073: Omega-3 Fatty Acid Levels and Risk for Incident Bleeding and Atrial Fibrillation: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation, 2020, 142, .	1.6	0
439	Abstract 14687: Achieved Eicosapentaenoic Acid (EPA) Levels Predicts Regression of Coronary Plaque Volumes by Coronary Computed Tomography Angiography (CCTA) in the EVAPORATE Trial. Circulation, 2020, 142, .	1.6	2
440	Abstract 15502: Clinical Outcomes in Patients Undergoing Non-cardiac Surgery Within 1 Year of Pci. Circulation, 2020, 142, .	1.6	0
441	Abstract 12923: Development of a Novel Biomarker-based Risk Score for Heart Failure in Patients With Diabetes. Circulation, 2020, 142, .	1.6	0
442	Abstract 16195: Socioeconomic Disadvantage is Associated With Higher Long-Term Cardiovascular Mortality Following Myocardial Infarction: The YOUNG-MI Registry. Circulation, 2020, 142, .	1.6	0
443	Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58. Circulation, 2020, 142, .	1.6	1
444	Abstract 15015: Eicosapentaenoic Acid, but Not Docosahexaenoic Acid or a Mixed Omega-3 Fatty Acid Supplement, Inhibits Low-density Lipoprotein Oxidation in a Time-dependent Manner. Circulation, 2020, 142, .	1.6	0
445	Abstract 16486: Consistent Cost-effectiveness of Icosapent Ethyl Across Patient Profiles From REDUCE-IT. Circulation, 2020, 142, .	1.6	0
446	Abstract 16749: Prevalence, Predictors, and Prognostic Implications of Left Ventricular Systolic Dysfunction Among Patients With STEMI in India: The Prospective NORIN-STEMI Registry. Circulation, 2020, 142, .	1.6	0
447	Abstract 14758: Contrasting Effects of Phospholipid Linked Eicosapentaenoic Acid and Arachidonic Acid on Membrane Structure and Stability. Circulation, 2020, 142, .	1.6	0
448	Abstract 13814: Semaglutide Reduces Mace Consistently Across Baseline Triglyceride Levels in Patients With Type 2 Diabetes: A Post Hoc Analysis of the Sustain 6 and Pioneer 6 Trials. Circulation, 2020, 142, .	1.6	0
449	Abstract 15389: Effect of Icosapent Ethyl on Changes in Coronary Plaque Characteristics at 9 Months in Patients With Elevated Triglycerides on Statin Therapy: Insights From EVAPORATE. Circulation, 2020, 142, .	1.6	4
450	Abstract 14799: Cardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 Trial. Circulation, 2020, 142, .	1.6	0

#	ARTICLE	IF	CITATIONS
451	Abstract 16407: Plasma Omega-3 Fatty Acids Predict Cardiovascular Events Stratified by Coronary Artery Calcium. <i>Circulation</i> , 2020, 142, .	1.6	0
452	COVID-19: An Unintended Force for Medical Revolution?. <i>Journal of Invasive Cardiology</i> , 2020, 32, E81-E82.	0.4	15
453	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019, 14, 270-281.	5.9	11
454	Prevalence and Outcomes of Undiagnosed Peripheral Arterial Disease Among High Risk Patients in Australia: An Australian REACH Sub-Study. <i>Heart Lung and Circulation</i> , 2019, 28, 939-945.	0.4	11
455	Patent foramen ovale and long-term risk of ischaemic stroke after surgery. <i>European Heart Journal</i> , 2019, 40, 914-924.	2.2	23
456	Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). <i>European Heart Journal</i> , 2019, 40, 2070-2085.	2.2	64
457	Balloon Predilation in Transcatheter Aortic Valve Replacement with Self-expanding Valves. <i>Structural Heart</i> , 2019, 3, 65-71.	0.6	0
458	Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007342.	3.9	10
459	Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction. <i>Circulation</i> , 2019, 140, 1004-1014.	1.6	70
460	The impact of randomized trial results on abdominal aortic aneurysm repair rates from 2003 to 2016: A population-based time-series analysis. <i>Vascular</i> , 2019, 27, 417-426.	0.9	3
461	Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1159-1161.	2.8	79
462	Effect of Systolic and Diastolic Blood Pressure on Cardiovascular Outcomes. <i>New England Journal of Medicine</i> , 2019, 381, 243-251.	27.0	408
463	Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1167-1176.	2.8	154
464	Cardiovascular Biomarkers After Metabolic Surgery Versus Medical Therapy for Diabetes. <i>Journal of the American College of Cardiology</i> , 2019, 74, 261-263.	2.8	15
465	Comparison of Outcomes in Elective Endovascular Aortic Repair vs Open Surgical Repair of Abdominal Aortic Aneurysms. <i>JAMA Network Open</i> , 2019, 2, e196578.	5.9	39
466	Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke. <i>JAMA Neurology</i> , 2019, 76, 1192.	9.0	70
467	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. <i>Gastroenterology</i> , 2019, 157, 682-691.e2.	1.3	299
468	Association of Coronary Anatomical Complexity With Clinical Outcomes After Percutaneous or Surgical Revascularization in the Veterans Affairs Clinical Assessment Reporting and Tracking Program. <i>JAMA Cardiology</i> , 2019, 4, 727.	6.1	22

#	ARTICLE	IF	CITATIONS
469	The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. <i>Clinical Cardiology</i> , 2019, 42, 797-805.	1.8	4
470	Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PPCI. <i>Journal of the American College of Cardiology</i> , 2019, 74, 83-99.	2.8	126
471	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 618-628.	11.4	207
472	Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3271-3280.	2.8	95
473	Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3281-3291.	2.8	36
474	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y ₁₂ Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1521-1537.	2.9	366
475	Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Gastroenterology</i> , 2019, 157, 403-412.e5.	1.3	108
476	A low-cost machine learning-based cardiovascular/stroke risk assessment system: integration of conventional factors with image phenotypes. <i>Cardiovascular Diagnosis and Therapy</i> , 2019, 9, 420-430.	1.7	54
477	Preventive Cardiology as a Subspecialty of Cardiovascular Medicine. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1926-1942.	2.8	39
478	Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis. <i>BMJ: British Medical Journal</i> , 2019, 367, l5476.	2.3	66
479	Antiarrhythmic Drugs or Catheter Ablation in the Management of Ventricular Tachyarrhythmias in Patients With Implantable Cardioverter-Defibrillators. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007600.	4.8	20
480	THEMIS and THEMIS-PCI. <i>European Heart Journal</i> , 2019, 40, 3378-3381.	2.2	15
481	The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. <i>Cell Metabolism</i> , 2019, 30, 847-849.	16.2	39
482	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005858.	2.2	17
483	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. <i>Circulation</i> , 2019, 140, 2054-2062.	1.6	83
484	Design and rationale of the North Indian STACS Segment Elevation Myocardial Infarction Registry: A prospective cohort study. <i>Clinical Cardiology</i> , 2019, 42, 1140-1146.	1.8	9
485	More CREDENCE for SGLT2 Inhibition. <i>Circulation</i> , 2019, 140, 1448-1450.	1.6	16
486	Personalized antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary intervention: A network meta-analysis of randomized clinical trials. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 181-186.	1.7	5

#	ARTICLE	IF	CITATIONS
487	Leadership in Cardiovascular Medicine. <i>European Heart Journal</i> , 2019, 40, 1395-1397.	2.2	0
488	Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1553-1561.	2.9	9
489	Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Circulation</i> , 2019, 140, 1693-1702.	1.6	371
490	Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 554-562.	2.1	26
491	Transcatheter Aortic Valve Replacement in Low-Risk Patients. <i>Circulation</i> , 2019, 140, 801-803.	1.6	17
492	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 1569-1577.	1.6	94
493	Hospital distance, socioeconomic status, and timely treatment of ischemic stroke. <i>Neurology</i> , 2019, 93, e747-e757.	1.1	28
494	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet, The</i> , 2019, 394, 1169-1180.	13.7	155
495	Ticagrelor in Patients with Stable Coronary Disease and Diabetes. <i>New England Journal of Medicine</i> , 2019, 381, 1309-1320.	27.0	255
496	Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1381.	7.4	144
497	SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus. <i>Cell Metabolism</i> , 2019, 30, 609-613.	16.2	69
498	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1177-1186.	2.8	49
499	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 1578-1589.	1.6	34
500	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. <i>Circulation</i> , 2019, 140, 1451-1459.	1.6	36
501	Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1519-1528.	2.8	30
502	Trends in the Use of Short-Term Mechanical Circulatory Support in the United States – An Analysis of the 2012 – 2015 National Inpatient Sample. <i>Structural Heart</i> , 2019, 3, 499-506.	0.6	5
503	Stability After Initial Decline in Coronary Revascularization Rates in the United States. <i>Annals of Thoracic Surgery</i> , 2019, 108, 1404-1408.	1.3	21
504	Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019, 4, 1092.	6.1	97

#	ARTICLE	IF	CITATIONS
505	Cardiovascular Toxicities of Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 2019, 74, 1714-1727.	2.8	124
506	Reply. Journal of the American College of Cardiology, 2019, 74, 1849-1850.	2.8	11
507	Fluorodeoxyglucose Uptake in Atheroma. Journal of the American College of Cardiology, 2019, 74, 1233-1236.	2.8	7
508	Birth and Maturation of Cardio-Oncology. JACC: CardioOncology, 2019, 1, 114-116.	4.0	12
509	Trends in Utilization of Surgical and Transcatheter Mitral Valve Repair in the United States†. American Journal of Cardiology, 2019, 123, 1187-1189.	1.6	6
510	Association of Triglyceride-Lowering LPL Variants and LDL-C Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA - Journal of the American Medical Association, 2019, 321, 364.	7.4	460
511	Stroke Outcomes in the COMPASS Trial. Circulation, 2019, 139, 1134-1145.	1.6	118
512	A New Dimension in the Relationship Between Procedural Volumes and Quality. Circulation, 2019, 139, 473-476.	1.6	5
513	Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial. Diabetes Care, 2019, 42, e42-e44.	8.6	25
514	Comparison of Clinical Care and In-Hospital Outcomes of Asian American and White Patients With Acute Ischemic Stroke. JAMA Neurology, 2019, 76, 430.	9.0	44
515	Long-term outcomes for heart failure patients with and without diabetes: From the Get With The Guidelines Heart Failure Registry. American Heart Journal, 2019, 211, 1-10.	2.7	17
516	Body Mass Index, Intensive Blood Pressure Management, and Cardiovascular Events in the SPRINT Trial. American Journal of Medicine, 2019, 132, 840-846.	1.5	18
517	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European Heart Journal, 2019, 40, 2801-2809.	2.2	45
518	Targeting RNA to lower triglycerides: long strides from short molecules. European Heart Journal, 2019, 40, 2797-2800.	2.2	10
519	Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. JAMA Cardiology, 2019, 4, 747.	6.1	198
520	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 200-206.	3.0	25
521	Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. Circulation, 2019, 140, 618-620.	1.6	96
522	Drug-eluting stents versus bare-metal stents with a single month of dual antiplatelet therapy: a trial sequential analysis. Journal of Thrombosis and Thrombolysis, 2019, 48, 11-13.	2.1	3

#	ARTICLE	IF	CITATIONS
523	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 606-617.	11.4	482
524	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. <i>Circulation</i> , 2019, 140, 529-537.	1.6	81
525	Aspirin for Primary Prevention of Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2915-2929.	2.8	89
526	Endoscopic versus Open Vein-Graft Harvesting for CABG. <i>New England Journal of Medicine</i> , 2019, 380, e43.	27.0	1
527	Trends in elective and ruptured abdominal aortic aneurysm repair by practice setting in Ontario, Canada, from 2003 to 2016: a population-based time-series analysis. <i>CMAJ Open</i> , 2019, 7, E379-E384.	2.4	4
528	Effects of Icosapent Ethyl on Total Ischemic Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2791-2802.	2.8	208
529	Response by DeFilippis et al to Letter Regarding Article, "Long-Term Outcomes After Out-of-Hospital Cardiac Arrest in Young Patients With Myocardial Infarction: Partners YOUNG-MI Registry". <i>Circulation</i> , 2019, 139, e996.	1.6	0
530	Temporal Trends and Outcomes of Hospitalizations With Prinzmetal Angina: Perspectives From a National Database. <i>American Journal of Medicine</i> , 2019, 132, 1053-1061.e1.	1.5	12
531	The relation between ABO blood types and clinical and platelet function parameters in patients who underwent percutaneous coronary intervention. <i>Coronary Artery Disease</i> , 2019, 30, 51-58.	0.7	7
532	The rise and fall of aspirin in the primary prevention of cardiovascular disease. <i>Lancet</i> , 2019, 393, 2155-2167.	13.7	140
533	A paradoxical relationship between hemoglobin A1C and in-hospital mortality in intracerebral hemorrhage patients. <i>Heliyon</i> , 2019, 5, e01659.	3.2	4
534	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 103-112.	1.6	107
535	Risk of obstructive coronary artery disease and major adverse cardiac events in patients with noncoronary atherosclerosis: Insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program. <i>American Heart Journal</i> , 2019, 213, 47-56.	2.7	8
536	Effect of Acclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1693.	7.4	25
537	Thrombolysis in young adults with stroke. <i>Neurology</i> , 2019, 92, e2784-e2792.	1.1	20
538	Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2439-2450.	2.8	69
539	Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 810-822.	4.5	18
540	Bariatric surgery is associated with a lower rate of death after myocardial infarction and stroke: A nationwide study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2058-2067.	4.4	37

#	ARTICLE	IF	CITATIONS
541	Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus. <i>Stroke</i> , 2019, 50, 1497-1503.	2.0	10
542	Vascular Regenerative Cell Exhaustion in Diabetes: Translational Opportunities to Mitigate Cardiometabolic Risk. <i>Trends in Molecular Medicine</i> , 2019, 25, 640-655.	6.7	19
543	REDUCE-IT. <i>European Heart Journal</i> , 2019, 40, 1174-1175.	2.2	31
544	Association of the New Peer Groupâ€‘Stratified Method With the Reclassification of Penalty Status in the Hospital Readmission Reduction Program. <i>JAMA Network Open</i> , 2019, 2, e192987.	5.9	42
545	Association of peripheral artery disease with inâ€‘hospital outcomes after endovascular transcatheter aortic valve replacement. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 249-255.	1.7	12
546	Arterial Inflammation. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1383-1385.	2.8	8
547	Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. <i>New England Journal of Medicine</i> , 2019, 380, 1825-1833.	27.0	96
548	Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y 12 Inhibitor Pretreatment. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007445.	3.9	0
549	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. <i>Circulation</i> , 2019, 139, 2516-2527.	1.6	224
550	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 2528-2536.	1.6	415
551	Two Randomized Clinical Trials on the Treatment of Secondary Mitral Regurgitationâ€‘Contradictory or Complementary?. <i>JAMA Cardiology</i> , 2019, 4, 311.	6.1	14
552	Association of Cardiovascular Disease With Respiratory Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2166-2177.	2.8	104
553	Outcomes and Resource Utilization for Nonelective Versus Elective Transcatheter Mitral Valve Repair. <i>American Journal of Cardiology</i> , 2019, 123, 1889-1891.	1.6	3
554	Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1596-1598.	2.8	38
555	Laboratory Monitoring of Antiplatelet Therapy. , 2019, , 653-682.		0
556	One- to 10-Day Versus 11- to 30-Day All-Cause Readmission and Mortality in Older Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2019, 123, 1840-1844.	1.6	1
557	Catheter Ablation for Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1255.	7.4	10
558	Trends in Performance and Opportunities for Improvement on a Composite Measure of Acute Myocardial Infarction Care. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e004983.	2.2	19

#	ARTICLE	IF	CITATIONS
559	Comparison of Sex-Based Differences in Home or Nonhome Discharge Utilization of Rehabilitative Services and Outcomes Following Transcatheter Aortic Valve Implantation in the United States. American Journal of Cardiology, 2019, 123, 1983-1991.	1.6	8
560	Metabolic Surgery for Hypertension in Patients With Obesity. Circulation Research, 2019, 124, 1009-1024.	4.5	39
561	Meta-analysis of Percutaneous Coronary Intervention Versus Medical Therapy in the Treatment of Coronary Chronic Total Occlusion. American Journal of Cardiology, 2019, 123, 2060-2062.	1.6	4
562	Wake Forest University long-term follow-up of type 2 myocardial infarction: The Wake-Up T2MI Registry. Clinical Cardiology, 2019, 42, 592-604.	1.8	5
563	Sham-Controlled Randomized Trials of Catheter-Based Renal Denervation in Patients With Hypertension. Journal of the American College of Cardiology, 2019, 73, 1633-1642.	2.8	69
564	Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y12 inhibition from the IABP-SHOCK II trial. Resuscitation, 2019, 137, 205-212.	3.0	31
565	Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. European Heart Journal, 2019, 40, 1553-1562.	2.2	62
566	Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clinical Cardiology, 2019, 42, 498-505.	1.8	24
567	Dual Antiplatelet Therapy Duration Based On Ischemic and Bleeding Risks After Coronary Stenting. Journal of the American College of Cardiology, 2019, 73, 741-754.	2.8	218
568	Frequency of 30-day readmission and its causes after percutaneous coronary intervention in acute myocardial infarction complicated by cardiogenic shock. Catheterization and Cardiovascular Interventions, 2019, 94, E67-E77.	1.7	11
569	Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. American Heart Journal, 2019, 212, 13-22.	2.7	13
570	Relation of Concomitant Heart Failure to Outcomes in Patients Hospitalized With Influenza. American Journal of Cardiology, 2019, 123, 1478-1480.	1.6	17
571	Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2019, 73, 1362-1364.	2.8	34
572	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2022-2031.	1.6	523
573	Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2019, 322, 2411.	7.4	232
574	Long-Term Cardiovascular Risk in Women With Hypertension During Pregnancy. Journal of the American College of Cardiology, 2019, 74, 2743-2754.	2.8	169
575	Coronary artery bypass grafting surgery versus percutaneous coronary intervention for coronary artery disease. The Cochrane Library, 2019, , .	2.8	0
576	Cardiometabolic risk reduction after metabolic surgery. Current Opinion in Cardiology, 2019, 34, 663-672.	1.8	3

#	ARTICLE	IF	CITATIONS
577	Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes. JACC: Cardiovascular Interventions, 2019, 12, 2346-2355.	2.9	13
578	Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation. JACC: Cardiovascular Interventions, 2019, 12, 2331-2341.	2.9	8
579	COMPASS for Vascular Surgeons. Current Opinion in Cardiology, 2019, 34, 178-184.	1.8	7
580	Cardiovascular risk reduction with icosapent ethyl. Current Opinion in Cardiology, 2019, 34, 721-727.	1.8	23
581	Temporal Trends and Outcomes of Transcatheter Mitral Valve Repair and Surgical Mitral Valve Intervention in Patients With Prior CABG. JACC: Cardiovascular Interventions, 2019, 12, 2445-2447.	2.9	6
582	Percutaneous Versus Surgical Pulmonic Valve Implantation for Right Ventricular Outflow Tract Dysfunction. Cardiovascular Revascularization Medicine, 2019, 20, 553-558.	0.8	4
583	Glycated Hemoglobin and Outcomes of Heart Failure (from Get With the Guidelines-Heart Failure). American Journal of Cardiology, 2019, 123, 618-626.	1.6	5
584	Frequency of 30-Day Readmission and Its Causes After Endovascular Aneurysm Intervention of Abdominal Aortic Aneurysm (from the Nationwide Readmission Database). American Journal of Cardiology, 2019, 123, 986-994.	1.6	7
585	Effect of Influenza on Outcomes in Patients With Heart Failure. JACC: Heart Failure, 2019, 7, 112-117.	4.1	64
586	CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials. Catheterization and Cardiovascular Interventions, 2019, 93, 1246-1252.	1.7	27
587	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2019, 380, 347-357.	27.0	4,159
588	Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine, 2019, 380, 11-22.	27.0	2,153
589	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet, The, 2019, 393, 31-39.	13.7	1,958
590	Randomized Trial of Endoscopic or Open Vein-Graft Harvesting for Coronary-Artery Bypass. New England Journal of Medicine, 2019, 380, 132-141.	27.0	92
591	Insights From Autopsies. JACC: Cardiovascular Imaging, 2019, 12, 146-148.	5.3	5
592	Thirty-Day Readmissions After Hospitalization for Hypertensive Emergency. Hypertension, 2019, 73, 60-67.	2.7	26
593	De-Escalation of Antiplatelet Therapy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 153-159.	2.0	9
594	Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. International Journal of Cardiology, 2019, 278, 217-222.	1.7	6

#	ARTICLE	IF	CITATIONS
595	Drug-Eluting Versus Bare-Metal Stents in Older Patients: A Meta-Analysis of Randomized Controlled Trials. Cardiovascular Revascularization Medicine, 2019, 20, 744-751.	0.8	5
596	Association of State Medicaid Expansion With Quality of Care and Outcomes for Low-Income Patients Hospitalized With Acute Myocardial Infarction. JAMA Cardiology, 2019, 4, 120.	6.1	40
597	Pulse Pressure, Cardiovascular Events, and Intensive Blood-Pressure Lowering in the Systolic Blood Pressure Intervention Trial (SPRINT). American Journal of Medicine, 2019, 132, 733-739.	1.5	21
598	Twenty Year Trends and Sex Differences in Young Adults Hospitalized With Acute Myocardial Infarction. Circulation, 2019, 139, 1047-1056.	1.6	393
599	Anticoagulation Following TAVR. Journal of the American College of Cardiology, 2019, 73, 22-28.	2.8	7
600	Linking Spontaneous Coronary Artery Dissection, Cervical Artery Dissection, and Fibromuscular Dysplasia. Journal of the American College of Cardiology, 2019, 73, 67-69.	2.8	6
601	Relation of Admission Blood Pressure to In-hospital and 90-Day Outcomes in Patients Presenting With Transient Ischemic Attack. American Journal of Cardiology, 2019, 123, 1083-1095.	1.6	4
602	Predictors of Hospital Cost After Transcatheter Aortic Valve Implantation in the United States: From the Nationwide Inpatient Sample Database. American Journal of Cardiology, 2019, 123, 1142-1148.	1.6	4
603	Prevalence, Presentation, and Associated Conditions of Patients With Fibromuscular Dysplasia. American Journal of Cardiology, 2019, 123, 1169-1172.	1.6	5
604	Transcatheter versus surgical aortic valve replacement in low-risk surgical patients: A meta-analysis of randomized clinical trials. Cardiovascular Revascularization Medicine, 2019, 20, 838-842.	0.8	17
605	Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion. Journal of the American College of Cardiology, 2019, 73, 121-130.	2.8	69
606	More Evidence That We Could All Use a Good Night's Sleep. Journal of the American College of Cardiology, 2019, 73, 145-147.	2.8	3
607	Meta-analysis Comparing Culprit Vessel Only Versus Multivessel Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction and Cardiogenic Shock. American Journal of Cardiology, 2019, 123, 218-226.	1.6	8
608	Components and Trends in Door to Treatment Times for Endovascular Therapy in Get With The Guidelines-Stroke Hospitals. Circulation, 2019, 139, 169-179.	1.6	34
609	Conditions and Factors Associated With Spontaneous Coronary Artery Dissection (from a National Tj ETQq1 1 0.784314 rgBT /Overl	1.6	51
610	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. Journal of the American College of Cardiology, 2019, 73, 387-396.	2.8	131
611	Restrictive versus liberal red blood cell transfusion for cardiac surgery: a systematic review and meta-analysis of randomized controlled trials. Journal of Thrombosis and Thrombolysis, 2019, 47, 179-185.	2.1	28
612	Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. Journal of Thrombosis and Thrombolysis, 2019, 47, 233-247.	2.1	32

#	ARTICLE	IF	CITATIONS
613	Safety and efficacy of transcatheter aortic valve replacement for native aortic valve regurgitation: A systematic review and meta-analysis. Catheterization and Cardiovascular Interventions, 2019, 93, 345-353.	1.7	22
614	Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). American Journal of Cardiology, 2019, 123, 145-152.	1.6	25
615	Practical considerations for cangrelor use in patients with acute coronary syndromes. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 39-44.	1.0	16
616	Pulse pressure in acute coronary syndromes: Comparative prognostic significance with systolic blood pressure. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 309-317.	1.0	6
617	Derivation and external validation of a simple risk tool to predict 30-day hospital readmissions after transcatheter aortic valve replacement. EuroIntervention, 2019, 15, 155-163.	3.2	12
618	Contemporary Patterns of Early Coronary Angiography Use in Patients With Non-ST-Segment Elevation Myocardial Infarction in the United States. JACC: Cardiovascular Interventions, 2018, 11, 369-380.	2.9	31
619	CABG the clear choice for patients with diabetes and multivessel disease. Lancet, The, 2018, 391, 913-914.	13.7	34
620	Sustained sex-based treatment differences in acute coronary syndrome care: Insights from the American Heart Association Get With The Guidelines Coronary Artery Disease Registry. Clinical Cardiology, 2018, 41, 758-768.	1.8	43
621	Transcatheter and Doppler waveform correlation in transcatheter aortic valve replacement. Open Heart, 2018, 5, e000728.	2.3	1
622	Segmental Arterial Mediolytic: An Important but Often Overlooked Cause of Multi-Vessel Thrombosis. American Journal of Medicine, 2018, 131, e231-e234.	1.5	2
623	Role of Invasive Functional Assessment in Surgical Revascularization of Coronary Artery Disease. Circulation, 2018, 137, 1731-1739.	1.6	10
624	Rediscovering the Orbit of Percutaneous Coronary Intervention After ORBITA. Circulation, 2018, 137, 2427-2429.	1.6	5
625	Sex and Racial Disparities in Cardiac Rehabilitation Referral at Hospital Discharge and Gaps in Long-Term Mortality. Journal of the American Heart Association, 2018, 7, .	3.7	65
626	Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2018, 11, e005635.	3.9	13
627	Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Prior Coronary Artery Bypass Grafting. Circulation: Cardiovascular Interventions, 2018, 11, e006179.	3.9	31
628	Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. European Heart Journal, 2018, 39, 1726-1735a.	2.2	133
629	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. Journal of the American College of Cardiology, 2018, 71, 489-496.	2.8	56
630	Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk. European Heart Journal, 2018, 39, 2255-2262.	2.2	45

#	ARTICLE	IF	CITATIONS
631	Risk of intracranial hemorrhage after carotid artery stenting versus endarterectomy: a population-based study. <i>Journal of Neurosurgery</i> , 2018, 129, 1522-1529.	1.6	11
632	Association of Preoperatively Diagnosed Patent Foramen Ovale With Perioperative Ischemic Stroke. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 452.	7.4	71
633	Metabolic Surgery. <i>Journal of the American College of Cardiology</i> , 2018, 71, 670-687.	2.8	130
634	Catheter ablation of ventricular tachycardia in nonischemic cardiomyopathy: A propensity score-matched analysis of in-hospital outcomes in the United States. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 771-779.	1.7	23
635	Baseline Blood Pressure, the 2017 ACC/AHA High Blood Pressure Guidelines, and Long-Term Cardiovascular Risk in SPRINT. <i>American Journal of Medicine</i> , 2018, 131, 956-960.	1.5	27
636	Long-Term Outcomes of Post-Operative Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 71, 749-751.	2.8	8
637	Subclinical Leaflet Thrombosis and Clinical Outcomes after TAVR: A Systematic Review and Meta-Analysis. <i>Structural Heart</i> , 2018, 2, 223-228.	0.6	9
638	Editorial commentary: Novel developments in revascularization for left main coronary artery disease. <i>Trends in Cardiovascular Medicine</i> , 2018, 28, 365-366.	4.9	0
639	Trends in Carotid Revascularization Procedures. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 307.	7.4	0
640	The Timing of P2Y 12 Inhibitor Initiation in the Treatment of ACS? Does the Evidence Exist in This Era?. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 471-477.	3.1	6
641	Cochrane corner: complete versus culprit-only revascularisation in ST segment elevation myocardial infarction with multivessel disease. <i>Heart</i> , 2018, 104, 1144-1147.	2.9	3
642	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. <i>American Heart Journal</i> , 2018, 200, 83-89.	2.7	117
643	Comparison of Survival After In-Hospital Cardiac Arrest in Patients With Versus Without Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2018, 121, 671-677.	1.6	6
644	Cardiovascular Risk and Statin Eligibility of Young Adults After an MI. <i>Journal of the American College of Cardiology</i> , 2018, 71, 292-302.	2.8	145
645	Appropriateness and Outcomes of Percutaneous Coronary Intervention at Top-Ranked and Nonranked Hospitals in the United States. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 342-350.	2.9	10
646	Metformin treatment decreases nitroxidative stress, restores nitric oxide bioavailability and endothelial function beyond glucose control. <i>Biomedicine and Pharmacotherapy</i> , 2018, 98, 149-156.	5.6	48
647	FFR-guided multivessel stenting reduces urgent revascularization compared with infarct-related artery only stenting in ST-elevation myocardial infarction: A meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2018, 252, 63-67.	1.7	9
648	Reply: Intersection of fasting plasma glucose, adverse cardiac remodeling, and clinical outcomes. <i>International Journal of Cardiology</i> , 2018, 252, 214-215.	1.7	1

#	ARTICLE	IF	CITATIONS
649	<scp>DECLAREâ€TIMI</scp> 58: Participantsâ€™ baseline characteristics. Diabetes, Obesity and Metabolism, 2018, 20, 1102-1110.	4.4	96
650	Contemporary Sex-Based Differences by Age in Presenting Characteristics, Use of an Early Invasive Strategy, and Inhospital Mortality in Patients With Nonâ€ST-Segmentâ€Elevation Myocardial Infarction in the United States. Circulation: Cardiovascular Interventions, 2018, 11, e005735.	3.9	47
651	Risks of Overinterpreting Interim Data. Circulation, 2018, 137, 206-209.	1.6	4
652	Causes of Troponin Elevation and Associated Mortality in Young Patients. American Journal of Medicine, 2018, 131, 284-292.e1.	1.5	29
653	LumenRECON Guidewire. Circulation: Cardiovascular Interventions, 2018, 11, e005333.	3.9	5
654	Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease. Circulation: Cardiovascular Interventions, 2018, 11, e005795.	3.9	25
655	Advances in atherosclerosis, atrial fibrillation, and valvular disease. Nature Reviews Cardiology, 2018, 15, 71-72.	13.7	5
656	External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. European Heart Journal, 2018, 39, 750-757a.	2.2	72
657	Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study. Catheterization and Cardiovascular Interventions, 2018, 92, E348-E355.	1.7	5
658	Trends in utilization of mechanical circulatory support in patients hospitalized after out-of-hospital cardiac arrest. Resuscitation, 2018, 127, 105-113.	3.0	34
659	Cocaine and Marijuana Use Among Young Adults With Myocardial Infarction. Journal of the American College of Cardiology, 2018, 71, 2540-2551.	2.8	118
660	Association of Electronic Health Record Use With Quality of Care and Outcomes in Heart Failure: An Analysis of Get With The Guidelinesâ€Heart Failure. Journal of the American Heart Association, 2018, 7, .	3.7	16
661	Aortic Valve Replacement in an Era of Rapid Innovation. Journal of the American College of Cardiology, 2018, 71, 1413-1416.	2.8	6
662	Is There Really a Benefit to Net Clinical Benefit in Testing Antithrombotics?. Circulation, 2018, 137, 1429-1431.	1.6	27
663	Association Between 30-Day Episode Payments and Acute Myocardial Infarction Outcomes Among Medicare Beneficiaries. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004397.	2.2	15
664	Diabetes Mellitus and Cardiogenic Shock Complicating Acute Myocardial Infarction. American Journal of Medicine, 2018, 131, 778-786.e1.	1.5	23
665	External validation of the TIMI risk score for secondary cardiovascular events among patients with recent myocardial infarction. Atherosclerosis, 2018, 272, 80-86.	0.8	24
666	Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 2018, 71, 2306-2315.	2.8	296

#	ARTICLE	IF	CITATIONS
667	Dual antiplatelet therapy in patients with an acute coronary syndrome: up to 12 months and beyond. European Heart Journal Supplements, 2018, 20, B21-B28.	0.1	2
668	Biomarkers enter the world of peripheral artery disease. European Heart Journal, 2018, 39, 2420-2422.	2.2	3
669	12 months of DAPT after acute coronary syndrome still beats 6 months. Lancet, The, 2018, 391, 1240-1242.	13.7	8
670	Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 158-165.	1.0	7
671	Long-term Outcomes of Carotid Endarterectomy Versus Stenting in a Multicenter Population-based Canadian Study. Annals of Surgery, 2018, 268, 364-373.	4.2	17
672	Relationship of Hospital Teaching Status with In-Hospital Outcomes for ST-Segment Elevation Myocardial Infarction. American Journal of Medicine, 2018, 131, 260-268.e1.	1.5	3
673	Meta-Analysis of Aspirin Versus Dual Antiplatelet Therapy Following Coronary Artery Bypass Grafting. American Journal of Cardiology, 2018, 121, 32-40.	1.6	32
674	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. Circulation, 2018, 137, 684-692.	1.6	22
675	Relationships Between Components of Blood Pressure and Cardiovascular Events in Patients with Stable Coronary Artery Disease and Hypertension. Hypertension, 2018, 71, 168-176.	2.7	41
676	Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial. European Journal of Heart Failure, 2018, 20, 359-369.	7.1	17
677	Effectiveness and Safety of Transcatheter Aortic Valve Implantation for Aortic Stenosis in Patients With "Porcelain" Aorta. American Journal of Cardiology, 2018, 121, 62-68.	1.6	9
678	Impact of flow, gradient, and left ventricular function on outcomes after transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2018, 91, 798-805.	1.7	14
679	Association between operator specialty and outcomes after carotid artery revascularization. Journal of Vascular Surgery, 2018, 67, 478-489.e6.	1.1	20
680	Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke: Updated Meta-Analysis of Randomized Clinical Trials. American Journal of Medicine, 2018, 131, 575-577.	1.5	37
681	A practical clinical approach to utilize cardiopulmonary exercise testing in the evaluation and management of coronary artery disease. Current Opinion in Cardiology, 2018, 33, 168-177.	1.8	22
682	Comparison of Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Chronic Kidney Disease. American Journal of Cardiology, 2018, 121, 343-348.	1.6	27
683	Increased Free Testosterone Levels in Men with Uncontrolled Type 2 Diabetes Five Years After Randomization to Bariatric Surgery. Obesity Surgery, 2018, 28, 277-280.	2.1	13
684	Thoracic endovascular repair versus medical management for acute uncomplicated type B aortic dissection. Catheterization and Cardiovascular Interventions, 2018, 91, 1138-1143.	1.7	12

#	ARTICLE	IF	CITATIONS
685	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2018, 391, 205-218.	13.7	426
686	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2018, 391, 219-229.	13.7	651
687	Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. <i>New England Journal of Medicine</i> , 2018, 378, 603-614.	27.0	399
688	Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure. <i>JAMA Cardiology</i> , 2018, 3, 44.	6.1	346
689	Enhanced Predictive Capability of a 1-Hour Oral Glucose Tolerance Test: A Prospective Population-Based Cohort Study. <i>Diabetes Care</i> , 2018, 41, 171-177.	8.6	88
690	Oral Antidiabetic Agents and Cardiovascular Outcomes. <i>Current Problems in Cardiology</i> , 2018, 43, 111-126.	2.4	4
691	Homograft versus Conventional Prosthesis for Surgical Management of Aortic Valve Infective Endocarditis. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2018, 13, 163-170.	0.9	0
692	Drug-Eluting Stents Versus Bare-Metal Stents in Saphenous Vein Graft Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e007045.	3.9	17
693	Response by Kumbhani et al to Letters Regarding Article, "Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure: Insights From Get With The Guidelines-Heart Failure". <i>Circulation</i> , 2018, 138, 2306-2307.	1.6	2
694	Art and Science in Registry Studies of Anemia and Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e007571.	3.9	1
695	UDI2Claims. <i>Journal of Patient Safety</i> , 2018, Publish Ahead of Print, e708-e715.	1.7	5
696	Homograft versus Conventional Prosthesis for Surgical Management of Aortic Valve Infective Endocarditis. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2018, 13, 163-170.	0.9	13
697	Long-Term Outcomes of Drug-Eluting Stents Versus Bare-Metal Stents in End-Stage Renal Disease Patients on Dialysis. <i>Cardiology in Review</i> , 2018, 26, 277-286.	1.4	4
698	Strategies to Reduce Acute Kidney Injury and Improve Clinical Outcomes Following Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 2254-2261.	2.9	22
699	Association of Rankings With Cardiovascular Outcomes at Top-Ranked Hospitals vs Nonranked Hospitals in the United States. <i>JAMA Cardiology</i> , 2018, 3, 1222.	6.1	22
700	Ross Procedure in Adults for Cardiologists and Cardiac Surgeons. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2761-2777.	2.8	135
701	Temperature and Precipitation Associate With Ischemic Stroke Outcomes in the United States. <i>Journal of the American Heart Association</i> , 2018, 7, e010020.	3.7	21
702	Characterizing High-Performing Articles by Altmetric Score in Major Cardiovascular Journals. <i>JAMA Cardiology</i> , 2018, 3, 1249.	6.1	31

#	ARTICLE	IF	CITATIONS
703	Electronic health records and outpatient cardiovascular disease care delivery: Insights from the American College of Cardiology's PINNACLE India Quality Improvement Program (PIQIP). Indian Heart Journal, 2018, 70, 750-752.	0.5	6
704	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine, 2018, 379, 2097-2107.	27.0	2,211
705	Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH Model. Journal of the American Heart Association, 2018, 7, e009217.	3.7	54
706	Prevalence of Elective and Ruptured Abdominal Aortic Aneurysm Repairs by Age and Sex From 2003 to 2016 in Ontario, Canada. JAMA Network Open, 2018, 1, e185418.	5.9	28
707	Trends in Inpatient Complications After Transcatheter and Surgical Aortic Valve Replacement in the Transcatheter Aortic Valve Replacement Era. Circulation: Cardiovascular Interventions, 2018, 11, e007517.	3.9	13
708	Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. Journal of the American Heart Association, 2018, 7, e009260.	3.7	8
709	Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. Journal of the American College of Cardiology, 2018, 72, 3370-3372.	2.8	102
710	Is RCT (Reverse Cholesterol Transport) Ready for an RCT (Randomized Controlled Trial)?. Journal of the American College of Cardiology, 2018, 72, 3270-3273.	2.8	3
711	Thin to Ultrathin. Circulation: Cardiovascular Interventions, 2018, 11, e007407.	3.9	1
712	Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes?. Cell Metabolism, 2018, 28, 813-815.	16.2	23
713	Coronary Bypass Surgery for Diabetes and Multivessel Disease. Journal of the American College of Cardiology, 2018, 72, 2838-2840.	2.8	3
714	30-Day Readmissions After Endovascular Thrombectomy for Acute Ischemic Stroke. JACC: Cardiovascular Interventions, 2018, 11, 2414-2424.	2.9	11
715	Toward Precision Policy – The Case of Cardiovascular Care. New England Journal of Medicine, 2018, 379, 2193-2195.	27.0	27
716	Long-Term Outcomes After Out-of-Hospital Cardiac Arrest in Young Patients With Myocardial Infarction. Circulation, 2018, 138, 2855-2857.	1.6	14
717	Rates, Characteristics, and Outcomes of Patients Transferred to Specialized Stroke Centers for Advanced Care. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e003359.	2.2	15
718	Management of Anticoagulation in Patients with Atrial Fibrillation Undergoing PCI: Double or Triple Therapy?. Current Cardiology Reports, 2018, 20, 110.	2.9	4
719	Public Reporting of Percutaneous Coronary Intervention Outcomes Done Differently – Leading From Washington? Reply. JAMA Cardiology, 2018, 3, 1127.	6.1	0
720	Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications. Canadian Journal of Physiology and Pharmacology, 2018, 96, 1184-1187.	1.4	21

#	ARTICLE	IF	CITATIONS
721	Hypoglycemia and Elevated Troponin in Patients With Diabetes and Coronary Artery Disease. Journal of the American College of Cardiology, 2018, 72, 1778-1786.	2.8	26
722	Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial). American Journal of Cardiology, 2018, 122, 1896-1901.	1.6	17
723	Meta-Analysis Evaluating the Effect of Left Coronary Dominance on Outcomes After Percutaneous Coronary Intervention. American Journal of Cardiology, 2018, 122, 2026-2034.	1.6	3
724	Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease?. Circulation, 2018, 138, 858-860.	1.6	5
725	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Circulation, 2018, 138, 2884-2894.	1.6	82
726	The perils of polyvascular disease in type 2 diabetes. Lancet Diabetes and Endocrinology, 2018, 6, 914-916.	11.4	8
727	Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke. Stroke, 2018, 49, 2237-2240.	2.0	25
728	Statins Reduce Abdominal Aortic Aneurysm Growth, Rupture, and Perioperative Mortality: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 2018, 7, e008657.	3.7	87
729	Association Between Statin Use and Cardiovascular Events After Carotid Artery Revascularization. Journal of the American Heart Association, 2018, 7, e009745.	3.7	30
730	Temporal Trends and Outcomes of Percutaneous Coronary Interventions in Nonagenarians. JACC: Cardiovascular Interventions, 2018, 11, 1872-1882.	2.9	23
731	Modes and timing of death in 66%252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. European Heart Journal, 2018, 39, 3810-3820.	2.2	28
732	Fractional Flow Reserve Measurement for the Physiological Assessment of Coronary Artery Stenosis Severity. JAMA - Journal of the American Medical Association, 2018, 320, 1275.	7.4	4
733	Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10854 patients from the CHAMPION PHOENIX trial. European Heart Journal, 2018, 39, 4112-4121.	2.2	49
734	Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity. American Journal of Cardiology, 2018, 122, 1959-1964.	1.6	53
735	Trends in Incidence, Characteristics, and In-Hospital Outcomes of Patients Presenting With Spontaneous Coronary Artery Dissection (From a National Population-Based Cohort Study Between 1998 and 2014). JAMA Cardiology, 2018, 3, 917.	6.1	50
737	The Reply. American Journal of Medicine, 2018, 131, e389-e390.	1.5	0
738	High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. American Heart Journal, 2018, 202, 97-103.	2.7	38

#	ARTICLE	IF	CITATIONS
739	Antithrombotic Therapy for Peripheral Artery Disease. Journal of the American College of Cardiology, 2018, 71, 2450-2467.	2.8	43
740	Percutaneous Coronary Intervention in 2018. JAMA - Journal of the American Medical Association, 2018, 319, 2127.	7.4	91
741	Comparison of Acute Ischemic Stroke Care and Outcomes Between Comprehensive Stroke Centers and Primary Stroke Centers in the United States. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004512.	2.2	63
742	Real-world revascularization therapy in heart failure: It's a jungle out there!. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 1422-1423.	0.8	1
743	Neighborhood Socioeconomic Disadvantage and Care After Myocardial Infarction in the National Cardiovascular Data Registry. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004054.	2.2	30
744	Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease. Circulation, 2018, 137, 2179-2183.	1.6	80
745	The Reply. American Journal of Medicine, 2018, 131, e263.	1.5	0
746	Catheter ablation of atrial fibrillation with heart failure: An updated meta-analysis of randomized trials. International Journal of Cardiology, 2018, 269, 170-173.	1.7	23
747	Association of the Affordable Care Act's Medicaid Expansion With Care Quality and Outcomes for Low-Income Patients Hospitalized With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004729.	2.2	31
748	The Current Landscape of Atrial Fibrillation and Atrial Flutter Clinical Trials. JACC: Clinical Electrophysiology, 2018, 4, 944-954.	3.2	5
749	Non-vitamin K antagonist oral anticoagulants in cardioversion of atrial fibrillation: a network meta-analysis. Journal of Thrombosis and Thrombolysis, 2018, 46, 134-138.	2.1	0
750	Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management. Journal of the American College of Cardiology, 2018, 72, 330-343.	2.8	152
751	Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials. Journal of Thrombosis and Thrombolysis, 2018, 46, 299-303.	2.1	18
752	Involvement of CD8+ T cell subsets in early response to vascular injury in patients with peripheral artery disease in vivo. Clinical Immunology, 2018, 194, 26-33.	3.2	11
753	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nature Reviews Cardiology, 2018, 15, 480-496.	13.7	180
754	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. Circulation, 2018, 138, 527-536.	1.6	211
755	Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate. American Journal of Medicine, 2018, 131, 1473-1481.	1.5	26
756	Coronary Microvascular Dysfunction and Cardiovascular Risk in Obese Patients. Journal of the American College of Cardiology, 2018, 72, 707-717.	2.8	103

#	ARTICLE	IF	CITATIONS
757	Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-“ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). American Journal of Cardiology, 2018, 122, 1322-1329.	1.6	2
758	Myocardial Scar But Not Ischemia Is Associated With Defibrillator Shocks and Sudden Cardiac Death in Stable Patients With Reduced Left Ventricular Ejection Fraction. JACC: Clinical Electrophysiology, 2018, 4, 1200-1210.	3.2	20
759	Meta-Analysis and Trial Sequential Analysis Comparing Percutaneous Ventricular Assist Devices Versus Intra-Aortic Balloon Pump During High-Risk Percutaneous Coronary Intervention or Cardiogenic Shock. American Journal of Cardiology, 2018, 122, 1330-1338.	1.6	42
760	Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial. Lancet, The, 2018, 391, 1997-2007.	13.7	70
761	Comparison of Causes and Associated Costs of 30-Day Readmission of Transcatheter Implantation Versus Surgical Aortic Valve Replacement in the United States (A National Readmission Database) Tj ETQq1 1 0.784314 rgBT14 Overlook	6.1	24
762	Public Reporting of Percutaneous Coronary Intervention Outcomes. JAMA Cardiology, 2018, 3, 635.	6.1	24
763	Left Ventricular Thrombus After Acute Myocardial Infarction. JAMA Cardiology, 2018, 3, 642.	6.1	171
764	Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials. Journal of Thrombosis and Thrombolysis, 2018, 46, 440-450.	2.1	84
765	Comparison of Outcomes of Transfemoral Versus Transapical Approach for Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2018, 122, 1520-1526.	1.6	32
766	Ross Procedure vs Mechanical Aortic Valve Replacement in Adults. JAMA Cardiology, 2018, 3, 978.	6.1	62
767	Aspirin“still the GLOBAL LEADER in antiplatelet therapy. Lancet, The, 2018, 392, 896-897.	13.7	6
768	Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. Circulation, 2018, 138, 1605-1607.	1.6	25
769	Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry. European Heart Journal, 2018, 39, 3855-3863.	2.2	21
770	The Reply. American Journal of Medicine, 2018, 131, e267-e268.	1.5	0
771	Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. International Journal of Cardiology, 2018, 270, 96-101.	1.7	10
772	Reduced-Intensity Anticoagulation for Mechanical Aortic Valve Prostheses. Journal of the American College of Cardiology, 2018, 71, 2727-2730.	2.8	4
773	Canagliflozin Improves the Recovery of Blood Flow in an Experimental Model of Severe Limb Ischemia. JACC Basic To Translational Science, 2018, 3, 327-329.	4.1	19
774	Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. EuroIntervention, 2018, 13, e1841-e1849.	3.2	16

#	ARTICLE	IF	CITATIONS
775	Contemporary parenteral antiplatelet bridging strategies: a single-centre real-world experience at a tertiary care centre. <i>EuroIntervention</i> , 2018, 14, e333-e335.	3.2	8
776	Long-Term Evaluation of the Effects of Acridinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2018, 5, 5-15.	0.7	7
777	Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 93-97.	1.0	19
778	Management and Outcomes of ST-Segment Elevation Myocardial Infarction in US Renal Transplant Recipients. <i>JAMA Cardiology</i> , 2017, 2, 250.	6.1	18
779	Leaflet Thrombosis in Surgically Explanted or Post-Mortem TAVR Valves. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 82-85.	5.3	42
780	Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 176-185.	2.8	47
781	Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2017, 69, 603-612.	2.8	121
782	Gastrointestinal Bleeding With Oral Anticoagulation: Understanding the Scope of the Problem. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 691-693.	4.4	22
783	Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11,473 patients. <i>European Heart Journal</i> , 2017, 38, ehv627.	2.2	138
784	Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke. <i>Circulation</i> , 2017, 135, 1024-1035.	1.6	48
785	New-Generation Coronary Stents: Current Data and Future Directions. <i>Current Atherosclerosis Reports</i> , 2017, 19, 14.	4.8	45
786	Complete or Culprit-Only Revascularization for Patients With Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 315-324.	2.9	127
787	Response by Hess et al to Letter Regarding Article, "Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Program." <i>Circulation</i> , 2017, 135, e22-e23.	1.6	2
788	Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. <i>Lancet, The</i> , 2017, 389, 1025-1034.	13.7	840
789	Timely Reperfusion in Stroke and Myocardial Infarction Is Not Correlated. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	3
790	Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main and Multivessel Coronary Artery Disease. <i>Circulation</i> , 2017, 135, 819-821.	1.6	19
791	Healthcare Resource Availability, Quality of Care, and Acute Ischemic Stroke Outcomes. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	17
792	Prognostic implications of fasting plasma glucose in subjects with echocardiographic abnormalities. <i>International Journal of Cardiology</i> , 2017, 241, 423-429.	1.7	9

#	ARTICLE	IF	CITATIONS
793	Association of Obesity With In-Hospital Mortality of Cardiogenic Shock Complicating Acute Myocardial Infarction. American Journal of Cardiology, 2017, 119, 1548-1554.	1.6	23
794	Delays in Door-to-Needle Times and Their Impact on Treatment Time and Outcomes in Get With The Guidelines-Stroke. Stroke, 2017, 48, 946-954.	2.0	81
795	Hypoglycaemia manifestations and recurrent events: <scp>L</scp>essons from the <scp>SAVOR&TILMI</scp> 53 outcome study. Diabetes, Obesity and Metabolism, 2017, 19, 1045-1050.	4.4	5
796	Bariatric Surgery versus Intensive Medical Therapy for Diabetes " 5-Year Outcomes. New England Journal of Medicine, 2017, 376, 641-651.	27.0	1,963
797	First-Generation Bioresorbable Vascular&Scaffolds. Journal of the American College of Cardiology, 2017, 69, 3067-3069.	2.8	9
798	The Management of Antiplatelet and Antithrombotic Regimens in Patients With Mechanical Valves Undergoing Percutaneous Coronary Intervention. JAMA Cardiology, 2017, 2, 713.	6.1	10
799	Overview of Coronary Heart Disease Risk Initiatives in South Asia. Current Atherosclerosis Reports, 2017, 19, 25.	4.8	7
800	Seasonal and circadian variations of acute myocardial infarction: Findings from the Get With The Guidelines"Coronary Artery Disease (GWTG-CAD) program. American Heart Journal, 2017, 189, 85-93.	2.7	58
801	Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention. Expert Opinion on Pharmacotherapy, 2017, 18, 875-883.	1.8	10
802	Association Between Hospital Volume and 30-Day Readmissions Following Transcatheter Aortic Valve Replacement. JAMA Cardiology, 2017, 2, 732.	6.1	68
803	Time-honored treatments for the initial management of acute coronary syndromes: Challenging the status quo. Trends in Cardiovascular Medicine, 2017, 27, 483-491.	4.9	6
804	Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. CMAJ Open, 2017, 5, E152-E177.	2.4	57
805	Complete versus culprit-only revascularisation in ST elevation myocardial infarction with multi-vessel disease. The Cochrane Library, 2017, 2017, CD011986.	2.8	18
806	Streamlining cardiovascular clinical trials to improve efficiency and generalisability. Heart, 2017, 103, 1156-1162.	2.9	10
807	Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors. JAMA Cardiology, 2017, 2, 127.	6.1	36
808	Cangrelor Use Since FDA&AApproval. Journal of the American College of Cardiology, 2017, 69, 463-464.	2.8	20
809	Outcomes and Temporal Trends of Inpatient Percutaneous Coronary Intervention at Centers With and Without On-site Cardiac Surgery in the United States. JAMA Cardiology, 2017, 2, 25.	6.1	45
810	My Approach to the patient with CAD and aspirin resistance. Trends in Cardiovascular Medicine, 2017, 27, 518-519.	4.9	2

#	ARTICLE	IF	CITATIONS
811	Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2017, 5, 483-493.	4.1	41
812	Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events. Clinical Cardiology, 2017, 40, 732-739.	1.8	10
813	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Canadian Journal of Cardiology, 2017, 33, 1027-1035.	1.7	133
814	Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry. Clinical Cardiology, 2017, 40, 710-718.	1.8	33
815	Examining the applicability of SPRINT in patients with subclinical or established atherothrombotic disease: A REACH registry analysis. International Journal of Cardiology, 2017, 243, 95-97.	1.7	4
816	Association Between Previous Use of Antiplatelet Therapy and Intracerebral Hemorrhage Outcomes. Stroke, 2017, 48, 1810-1817.	2.0	52
817	How I use laboratory monitoring of antiplatelet therapy. Blood, 2017, 130, 713-721.	1.4	42
818	Coronary CTA in the Evaluation of Stable Chest Pain. Journal of the American College of Cardiology, 2017, 69, 1771-1773.	2.8	13
819	Letter by Taqueti and Bhatt Regarding Article, "Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study". Circulation, 2017, 135, e864-e865.	1.6	0
820	Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria. European Heart Journal, 2017, 38, 3211-3218.	2.2	33
821	Blood pressure and cardiovascular outcomes: a closer look " Authors' reply. Lancet, The, 2017, 389, 1296-1297.	13.7	0
822	Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. Diabetes Research and Clinical Practice, 2017, 130, 24-33.	2.8	22
823	A heart within a heart. Catheterization and Cardiovascular Interventions, 2017, 89, 1239-1241.	1.7	0
824	Comparison of Delay Times from Symptom Onset to Medical Contact in Blacks Versus Whites With Acute Myocardial Infarction. American Journal of Cardiology, 2017, 119, 1127-1134.	1.6	22
825	Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes. Heart, 2017, 103, 1168-1176.	2.9	34
826	Meta-analysis of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Left Main Coronary Artery Disease. American Journal of Cardiology, 2017, 119, 1949-1956.	1.6	19
827	Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization. American Heart Journal, 2017, 188, 156-166.	2.7	10
828	Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2017, 317, 1057.	7.4	179

#	ARTICLE	IF	CITATIONS
829	Rationale and design of <scp>REDUCEâ€”T</scp>: Reduction of Cardiovascular Events with Icosapent Ethylâ€”Intervention Trial. Clinical Cardiology, 2017, 40, 138-148.	1.8	154
830	Hydrophilic vs lipophilic statins in coronary artery disease: A meta-analysis of randomized controlled trials. Journal of Clinical Lipidology, 2017, 11, 624-637.	1.5	30
831	Impact of continuous positive airway pressure and oxygen on health status in patients with coronary heart disease, cardiovascular risk factors, and obstructive sleep apnea: A Heart Biomarker Evaluation in Apnea Treatment (HEARTBEAT) analysis. American Heart Journal, 2017, 189, 59-67.	2.7	24
832	Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. International Journal of Cardiology, 2017, 241, 87-96.	1.7	24
833	Assessment of Stable Coronary Lesions. New England Journal of Medicine, 2017, 376, 1879-1881.	27.0	22
834	Microangiopathy, Arterial Stiffness, and Risk Stratification in Patients With Type 2 Diabetesâ€”Reply. JAMA Cardiology, 2017, 2, 821.	6.1	0
835	Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet, The, 2017, 389, 2383-2392.	13.7	718
836	Potent P2Y ₁₂ Inhibitors in Menâ€”Versusâ€”Women. Journal of the American College of Cardiology, 2017, 69, 1549-1559.	2.8	51
837	Differences in Acute Ischemic Stroke Quality of Care and Outcomes by Primary Stroke Center Certification Organization. Stroke, 2017, 48, 412-419.	2.0	41
838	Thirty-Day Readmissions After Transcatheter Aortic Valve Replacement in the United States. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	128
839	Trends in Palliative Care Use in Elderly Men and Women With Severe Heart Failure in the United Statesâ€”Reply. JAMA Cardiology, 2017, 2, 344.	6.1	3
840	Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	6
841	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptorâ€”Inhibiting Therapies. Circulation, 2017, 136, 1955-1975.	1.6	293
842	2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Nonâ€”ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2017, 70, 2048-2090.	2.8	146
843	Heart Rate and Outcomes in Hospitalizedâ€”Patients With Heart Failure With Preserved Ejectionâ€”Fraction. Journal of the American College of Cardiology, 2017, 70, 1861-1871.	2.8	34
844	Predicting Risk in ACS. Journal of the American College of Cardiology, 2017, 70, 1858-1860.	2.8	2
845	Increase in Endovascular Therapy in Get With The Guidelines-Stroke After the Publication of Pivotal Trials. Circulation, 2017, 136, 2303-2310.	1.6	106
846	Age Differences in Hospital Mortality for Acute Myocardial Infarction: Implications for Hospital Profiling. Annals of Internal Medicine, 2017, 167, 555.	3.9	8

#	ARTICLE	IF	CITATIONS
847	Taking the "Public" Out of Public Reporting of Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2017, 318, 1439.	7.4	13
848	How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD. Journal of the American College of Cardiology, 2017, 70, 2171-2185.	2.8	59
849	Association of Chronic Kidney Disease With In-Hospital Outcomes of Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2017, 10, 2050-2060.	2.9	106
850	CANTOS Ushers in a New Calculus of Inflammasome Targeting for Vascular Protection and Maybe More. Cell Metabolism, 2017, 26, 703-705.	16.2	30
851	The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum. European Heart Journal, 2017, 38, 3488-3492.	2.2	94
852	Rationale and design of the Drug-Eluting Stents vs Bare-Metal Stents in Saphenous Vein Graft Angioplasty (DIVA) Trial. Clinical Cardiology, 2017, 40, 946-954.	1.8	10
853	Cangrelor Use in Cardiogenic Shock. JACC: Cardiovascular Interventions, 2017, 10, 1712-1714.	2.9	22
854	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. New England Journal of Medicine, 2017, 377, 1513-1524.	27.0	1,099
855	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 1319-1330.	27.0	1,745
856	Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy. JACC: Cardiovascular Interventions, 2017, 10, 1621-1630.	2.9	19
857	Clinical or Symptomatic Leaflet Thrombosis Following Transcatheter Aortic Valve Replacement: Insights from the U.S. FDA MAUDE Database. Structural Heart, 2017, 1, 256-264.	0.6	33
858	Integrated Noninvasive Physiological Assessment of Coronary Circulatory Function and Impact on Cardiovascular Mortality in Patients With Stable Coronary Artery Disease. Circulation, 2017, 136, 2325-2336.	1.6	193
859	What Is the Optimal Revascularization Strategy for Left Main Coronary Stenosis?. JAMA Cardiology, 2017, 2, 1061.	6.1	7
860	Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. Journal of the American College of Cardiology, 2017, 70, 1368-1375.	2.8	74
861	Safety and Tolerability of Transitioning from Cangrelor to Ticagrelor in Patients Who Underwent Percutaneous Coronary Intervention. American Journal of Cardiology, 2017, 120, 359-361.	1.6	10
862	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION) Tj ETQq0 0 0 rgBT / Overlock 10 Tf 50 142	1.6	12
863	Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events. Clinical Cardiology, 2017, 40, 932-939.	1.8	43
864	Impact of total occlusion of culprit artery in acute non-ST elevation myocardial infarction: a systematic review and meta-analysis. European Heart Journal, 2017, 38, 3082-3089.	2.2	103

#	ARTICLE	IF	CITATIONS
865	Study of young patients with myocardial infarction: Design and rationale of the YOUNG-MI Registry. <i>Clinical Cardiology</i> , 2017, 40, 955-961.	1.8	39
866	Regional Variation in Utilization, In-hospital Mortality, and Health-Care Resource Use of Transcatheter Aortic Valve Implantation in the United States. <i>American Journal of Cardiology</i> , 2017, 120, 1869-1876.	1.6	17
867	Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	7
868	Primary Prevention of Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2992-2994.	2.8	26
869	Do We Need a Trial of DES Versus CABG Surgery in Diabetic Patients With ACS?. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3007-3009.	2.8	12
870	Culprit Vesselâ€œOnly Versus Multivessel Percutaneous Coronary Intervention in Patients With Cardiogenic Shock Complicating ST-Segmentâ€œElevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	44
871	Use of Cardiac Computerized Tomography to Predict Neoâ€œLeft Ventricular Outflow Tract Obstruction Before Transcatheter Mitral Valve Replacement. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	52
872	Role of Hospital Volumes in Identifying Low-Performing and High-Performing Aortic and Mitral Valve Surgical Centers in the United States. <i>JAMA Cardiology</i> , 2017, 2, 1322.	6.1	44
873	Comparison of Outcomes of ST-Elevation Myocardial Infarction Treated by Percutaneous Coronary Intervention During Off-Hours Versus On-Hours. <i>American Journal of Cardiology</i> , 2017, 120, 1742-1754.	1.6	18
874	Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1648-1659.	1.8	18
875	Blood pressure and in-hospital outcomes in patients presenting with ischaemic stroke. <i>European Heart Journal</i> , 2017, 38, 2827-2835.	2.2	51
876	O PIONEERS!. <i>Circulation</i> , 2017, 135, 334-337.	1.6	27
877	Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2017, 40, 69-76.	8.6	205
878	Sex and Age Interactions and Differences in Outcomes After Intracerebral Hemorrhage. <i>Journal of Women's Health</i> , 2017, 26, 380-388.	3.3	17
879	Prediction of 30-Day All-Cause Readmissions in Patients Hospitalized for Heart Failure. <i>JAMA Cardiology</i> , 2017, 2, 204.	6.1	249
880	The Wrong Toothpaste and the Painful Burp. <i>American Journal of Medicine</i> , 2017, 130, e19-e20.	1.5	0
881	Optimizing the Use of Cangrelor in the Real World. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 5-16.	2.2	7
882	Shortâ€œversus longâ€œterm Dual Antiplatelet therapy after drugâ€œeluting stent implantation in women versus men: A sexâ€œspecific patientâ€œlevel pooledâ€œanalysis of six randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 178-189.	1.7	18

#	ARTICLE	IF	CITATIONS
883	Optimal Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Interventional Cardiology Clinics</i> , 2017, 6, 25-37.	0.4	8
884	Thirty-Day Readmission Rate and Costs After Percutaneous Coronary Intervention in the United States. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	49
885	Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. <i>Thrombosis and Haemostasis</i> , 2017, 117, 940-947.	3.4	21
886	Differences in Dynamic Diurnal Blood Pressure Variability Between Japanese and American Treatment-Resistant Hypertensive Populations. <i>Circulation Journal</i> , 2017, 81, 1337-1345.	1.6	25
887	Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. <i>European Heart Journal</i> , 2016, 37, ehv443.	2.2	293
888	Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. <i>European Heart Journal</i> , 2016, 37, ehv482.	2.2	70
889	Quantifying the 3 Biases That Lead to Unintentional Overestimation of the Blood Pressureâ€“Lowering Effect of Renal Denervation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 14-22.	2.2	36
890	Highlights from the 65th American College of Cardiology Annual Scientific Session (ACC 2016). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 142-144.	3.0	1
891	Concurrent Lower Gastrointestinal Bleeding Risk and Myocardial Ischemic Risk: Resume Aspirin or Not?. <i>Gastroenterology</i> , 2016, 151, 222-225.	1.3	1
892	Adaptive Designs for Clinical Trials. <i>New England Journal of Medicine</i> , 2016, 375, 65-74.	27.0	335
893	<scp>Frequency</scp> and Implications of Ischemia Prior to Ventricular Tachyarrhythmia in Patients Treated With a Wearable Cardioverter Defibrillator Following Myocardial Infarction. <i>Clinical Cardiology</i> , 2016, 39, 399-405.	1.8	6
894	Impact of Insurance Status on Outcomes and Use of Rehabilitation Services in Acute Ischemic Stroke: Findings From Get With The Guidelinesâ€“Stroke. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	46
895	Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease. <i>Annals of Internal Medicine</i> , 2016, 164, 155.	3.9	34
896	Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless ofÂAspirin Dose in Patients Requiring DualÂAntiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1661-1671.	2.8	69
897	Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2016, 39, 1329-1337.	8.6	12
898	Cardiovascular health awareness and the effect of an educational intervention on school-aged children in a rural district of India. <i>Indian Heart Journal</i> , 2016, 68, 43-47.	0.5	15
899	Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2016, 133, 2094-2098.	1.6	19
900	Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2719-2728.	2.8	303

#	ARTICLE	IF	CITATIONS
901	Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS—TIMI 54. Journal of the American College of Cardiology, 2016, 67, 2732-2740.	2.8	179
902	Stroke Prevention in Atrial Fibrillation in Patients With Chronic Kidney Disease. Circulation, 2016, 133, 1512-1515.	1.6	28
903	Percutaneous Coronary Intervention in Native Coronary Arteries Versus Bypass Grafts in Patients With Prior Coronary Artery Bypass Graft Surgery. JACC: Cardiovascular Interventions, 2016, 9, 884-893.	2.9	122
904	Smoker's Paradox in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Journal of the American Heart Association, 2016, 5, .	3.7	62
905	Mechanical Thrombectomy and Functional Outcomes After Stroke. JAMA - Journal of the American Medical Association, 2016, 315, 1791.	7.4	1
906	Hospital Variation in Premature Clopidogrel Discontinuation After Drug-Eluting Stent Placement in the Veterans Affairs (VA) Healthcare System. Journal of the American Heart Association, 2016, 5, .	3.7	4
907	Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or <scp>TIA</scp>: Insights From the <scp>REACH</scp> Registry. Clinical Cardiology, 2016, 39, 670-677.	1.8	45
908	Off-Hours Versus On-Hours Presentation in ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2016, 68, 2385-2387.	2.8	6
909	Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. Journal of the American College of Cardiology, 2016, 68, 1851-1864.	2.8	319
910	Ticagrelor for patients with acute coronary syndromes: PLATonic affair or lasting SWEDHEART?. European Heart Journal, 2016, 37, 3343-3346.	2.2	10
911	Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk. JAMA Cardiology, 2016, 1, 989.	6.1	77
912	Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Journal of the American Heart Association, 2016, 5, .	3.7	53
913	Accreditation and funding for a 24-month advanced interventional cardiology fellowship program: A call to action for optimal training of the next generation of interventionalists. Catheterization and Cardiovascular Interventions, 2016, 88, 1010-1015.	1.7	15
914	Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. American Heart Journal, 2016, 182, 28-35.	2.7	12
915	Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions. Circulation, 2016, 134, 723-733.	1.6	31
916	Prior Antithrombotic Use Is Associated With Favorable Mortality and Functional Outcomes in Acute Ischemic Stroke. Stroke, 2016, 47, 2066-2074.	2.0	12
917	Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure. Circulation, 2016, 134, 517-526.	1.6	90
918	Use and Outcomes of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients ≥90 Years of Age. Stroke, 2016, 47, 2347-2354.	2.0	27

#	ARTICLE	IF	CITATIONS
919	Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the <scp>TRILOGY ACS</scp> Trial. <i>Clinical Cardiology</i> , 2016, 39, 497-506.	1.8	5
920	Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. <i>European Heart Journal</i> , 2016, 38, ehv325.	2.2	104
921	Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. <i>Lancet, The</i> , 2016, 388, 2142-2152.	13.7	357
922	Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction. <i>Circulation</i> , 2016, 134, 861-871.	1.6	40
923	Design and Rationale of the <scp>REâ€œDUAL PCI</scp> Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. <i>Clinical Cardiology</i> , 2016, 39, 555-564.	1.8	65
924	Routine invasive versus selective invasive strategies for Nonâ€œSTâ€œelevation acute coronary syndromes: An Updated metaâ€œanalysis of randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 765-774.	1.7	23
925	Trends in 30-Day Readmission Rates for Patients Hospitalized With Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	127
926	Response by Bagai et al to Letter Regarding Article, â€œIndividualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Interventionâ€œ. <i>Circulation</i> , 2016, 134, e334-e335.	1.6	0
927	Why are acute ischemic stroke patients not receiving IV tPA?. <i>Neurology</i> , 2016, 87, 1565-1574.	1.1	159
928	Troponin and the J-Curve of Diastolicâ€œBlood Pressure. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1723-1726.	2.8	32
929	Hospital Variation in Home-Time After Acute Ischemic Stroke. <i>Stroke</i> , 2016, 47, 2627-2633.	2.0	33
930	Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelinesâ€œHeart Failure registry. <i>American Heart Journal</i> , 2016, 182, 9-20.	2.7	115
931	Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acuteâ€œCoronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1905-1913.	2.9	38
932	Sleep Duration and Quality: Impact on Lifestyle Behaviors and Cardiometabolic Health: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2016, 134, e367-e386.	1.6	602
933	Trends in Palliative Care Use in Veterans With Severe Heart Failure Using a Large National Cohort. <i>JAMA Cardiology</i> , 2016, 1, 617.	6.1	34
934	Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	19
935	Regression to the Mean in SYMPLICITYâ€œHTN-3. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2016-2025.	2.8	50
936	Do Acute Myocardial Infarction and Heart Failure Readmissions Flagged as Potentially Preventable by the 3M Potentially Preventable Readmissions Software Have More Process-of-Care Problems?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 532-541.	2.2	5

#	ARTICLE	IF	CITATIONS
937	Guideline-Appropriate Care and In-Hospital Outcomes in Patients With Heart Failure in Teaching and Nonteaching Hospitals. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 757-766.	2.2	22
938	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	83
939	On the use of propensity scores in case of rare exposure. <i>BMC Medical Research Methodology</i> , 2016, 16, 38.	3.1	25
940	Fractional Flow Reserve in Serial Coronary Artery Stenoses. <i>JAMA Cardiology</i> , 2016, 1, 359.	6.1	10
941	Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	10
942	Relation of Obesity to Survival After In-Hospital Cardiac Arrest. <i>American Journal of Cardiology</i> , 2016, 118, 662-667.	1.6	36
943	Future prospects for renal artery denervation. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 393-395.	2.3	1
944	Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events. <i>JAMA Cardiology</i> , 2016, 1, 425.	6.1	88
945	Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention. <i>Circulation</i> , 2016, 133, 248-255.	1.6	26
946	Pulse Pressure and Risk for Cardiovascular Events in Patients With Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2016, 67, 392-403.	2.8	120
947	Aspirin and proton-pump inhibitors: interpreting the interplay. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 20-22.	3.0	7
948	Distinct Short-Term Outcomes in Patients With Mild Versus Rapidly Improving Stroke Not Treated With Thrombolytics. <i>Stroke</i> , 2016, 47, 1278-1285.	2.0	16
949	Heart failure event definitions in drug trials in patients with type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 294-296.	11.4	26
950	Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding. <i>Journal of the American College of Cardiology</i> , 2016, 67, 596-598.	2.8	25
951	Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2016, 67, 936-947.	2.8	35
952	Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	24
953	Simultaneous Platelet P2Y ₁₂ and P2Y ₁ ADP Receptor Blockade. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 427-428.	2.4	5
954	Clinical Effectiveness of Hydralazine+Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. <i>Circulation: Heart Failure</i> , 2016, 9, e002444.	3.9	29

#	ARTICLE	IF	CITATIONS
955	Sex and Race/Ethnicity-Related Disparities in Care and Outcomes After Hospitalization for Coronary Artery Disease Among Older Adults. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, S36-44.	2.2	57
956	Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1145-1154.	2.8	108
957	Statin use, intensity, and 3-year clinical outcomes among older patients with coronary artery disease. <i>American Heart Journal</i> , 2016, 173, 27-34.	2.7	17
958	The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. <i>European Heart Journal</i> , 2016, 37, 1122-1130.	2.2	23
959	Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y ₁₂ inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2016, 37, 1133-1142.	2.2	138
960	Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. <i>American Journal of Medicine</i> , 2016, 129, 340.e1-340.e8.	1.5	34
961	Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2015, 38, 696-705.	8.6	141
962	Late breaking trials of 2014 in coronary artery disease: Commentary covering <scp>ACC</scp>, Euro<scp>PCR</scp>, <scp>SCAI</scp>, <scp>TCT</scp>, <scp>ESC</scp>, and <scp>AHA</scp>. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 73-79.	1.7	0
963	Yes, hyperglycaemia is indeed a modifiable cardiac risk factor: so says Mendel. <i>European Heart Journal</i> , 2015, 36, 1424-1427.	2.2	5
964	Myocardial Bridging in a Man With Non-ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2015, 131, e373-4.	1.6	4
965	Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus. <i>Circulation</i> , 2015, 132, 2345-2350.	1.6	42
966	Mechanical Thrombectomy for Acute Ischemic Stroke. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2498-2505.	2.8	53
967	Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure. <i>Hypertension</i> , 2015, 66, 1130-1137.	2.7	42
968	Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. <i>Journal of the American Heart Association</i> , 2015, 4, e002061.	3.7	14
969	Association of Chronic Renal Insufficiency With In-Hospital Outcomes After Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2015, 4, e002069.	3.7	48
970	Racial/Ethnic and Sex Differences in Emergency Medical Services Transport Among Hospitalized US Stroke Patients: Analysis of the National Get With The Guidelines Stroke Registry. <i>Journal of the American Heart Association</i> , 2015, 4, e002099.	3.7	69
971	Interaction between diabetes and a high ankle-brachial index on mortality risk. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 615-621.	1.8	18
972	Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study. <i>BMJ</i> , The, 2015, 351, h3786.	6.0	54

#	ARTICLE	IF	CITATIONS
973	Response to Letter Regarding Article, “Aspiration Thrombectomy Beneficial in Patients Undergoing Primary Percutaneous Coronary Intervention? Meta-Analysis of Randomized Trials” Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	1
974	Balancing the risks of stroke and bleeding in CKD. Nature Reviews Nephrology, 2015, 11, 200-202.	9.6	22
975	Primary Prevention Implantable Cardioverter-Defibrillators in Older Racial and Ethnic Minority Patients. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 145-151.	4.8	14
976	Clinical Effectiveness of Statin Therapy After Ischemic Stroke: Primary Results From the Statin Therapeutic Area of the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. Circulation, 2015, 132, 1404-1413.	1.6	43
977	Characteristics, quality of care, and in-hospital outcomes of Asian-American heart failure patients: Findings from the American Heart Association Get With The Guidelines-Heart Failure Program. International Journal of Cardiology, 2015, 189, 141-147.	1.7	4
978	Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death. Circulation, 2015, 132, 923-931.	1.6	397
979	Cardiovascular Risk Factors and In-hospital Mortality in Acute Coronary Syndromes: Insights From the Canadian Global Registry of Acute Coronary Events. Canadian Journal of Cardiology, 2015, 31, 1455-1461.	1.7	37
980	Gaps in Referral to Cardiac Rehabilitation of Patients Undergoing Percutaneous Coronary Intervention in the United States. Journal of the American College of Cardiology, 2015, 65, 2079-2088.	2.8	130
981	Warfarin in patients on haemodialysis with atrial fibrillation—friend or foe?. Nature Reviews Nephrology, 2015, 11, 450-450.	9.6	0
982	Is Aspiration Thrombectomy Beneficial in Patients Undergoing Primary Percutaneous Coronary Intervention?. Circulation: Cardiovascular Interventions, 2015, 8, e002258.	3.9	74
983	Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 383-392.	2.2	52
984	Expanding the Boundaries of Heart Failure Care with Interventional and Device Therapy. Heart Failure Clinics, 2015, 11, xiii.	2.1	1
985	Do We Really Know the CvLPRIT in Myocardial Infarction? Or Just Stent All Lesions?—. Journal of the American College of Cardiology, 2015, 65, 973-975.	2.8	13
986	When Is a Double Better Than a TRIPLE?. Journal of the American College of Cardiology, 2015, 65, 1630-1632.	2.8	19
987	Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin. JACC: Cardiovascular Interventions, 2015, 8, 424-433.	2.9	35
988	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 2015, 372, 1791-1800.	27.0	1,585
989	Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study. European Journal of Preventive Cardiology, 2015, 22, 317-325.	1.8	94
990	Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial. Diabetes Care, 2015, 38, 1145-1153.	8.6	73

#	ARTICLE	IF	CITATIONS
991	Regional Variation in the Incidence and Outcomes of In-Hospital Cardiac Arrest in the United States. <i>Circulation</i> , 2015, 131, 1415-1425.	1.6	118
992	Trends in Management and Outcomes of ST-Elevation Myocardial Infarction in Patients With End-Stage Renal Disease in the United States. <i>American Journal of Cardiology</i> , 2015, 115, 1033-1041.	1.6	28
993	Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 356-366.	11.4	224
994	Moving Toward Global Primordial Prevention in Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1535-1537.	2.8	29
995	Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. <i>New England Journal of Medicine</i> , 2015, 373, 2015-2024.	27.0	874
996	Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2015, 38, 2142-2150.	8.6	54
997	Quality of Care and Ischemic Stroke Risk After Hospitalization for Transient Ischemic Attack. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, S117-S124.	2.2	15
998	Smoking Paradox in Patients Hospitalized With Coronary Artery Disease or Acute Ischemic Stroke. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, S73-80.	2.2	28
999	An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPPLICITY HTN-3 trial. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 769-779.	2.3	36
1000	Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial" <i>Circulation</i> , 2015, 132, e121-2.	1.6	61
1001	ACC/AHA/STS Statement on the Future of Registries and the Performance Measurement Enterprise. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2230-2245.	2.8	95
1002	Temporal Trends and Sex Differences in Revascularization and Outcomes of ST-Segment Elevation Myocardial Infarction in Younger Adults in the United States. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1961-1972.	2.8	196
1003	Culprit-Only vs. Complete Revascularization During ST-Segment Elevation Myocardial Infarction. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 260-266.	3.1	12
1004	Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. <i>New England Journal of Medicine</i> , 2015, 373, 610-620.	27.0	229
1005	Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures. <i>Circulation</i> , 2015, 132, 1347-1353.	1.6	81
1006	Biomechanical Modeling to Improve Coronary Artery Bifurcation Stenting. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1281-1296.	2.9	84
1007	Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 317-322.	2.1	26
1008	Temporal Trends for Secondary Prevention Measures Among Patients Hospitalized with Coronary Artery Disease. <i>American Journal of Medicine</i> , 2015, 128, 426.e1-426.e9.	1.5	31

#	ARTICLE	IF	CITATIONS
1009	Targeted versus standard feedback: Results from a Randomized Quality Improvement Trial. American Heart Journal, 2015, 169, 132-141.e2.	2.7	9
1010	Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal, 2015, 36, 219-227.	2.2	458
1011	Should patients stop taking aspirin for primary prevention?. Cleveland Clinic Journal of Medicine, 2015, 82, 91-96.	1.3	4
1012	Abstract 12509: Initial Reports on the Safety of Intravenous Tissue Plasminogen Activator in Acute Ischemic Stroke Patients Taking Novel Oral Anticoagulants (NOACs). Circulation, 2015, 132, .	1.6	1
1013	Medical management of peripheral artery disease in diabetes mellitus. European Heart Journal, 2015, 36, 1494-5.	2.2	5
1014	Heads Up! Introducing Wearable Health Technologies in Cardiology. Journal of Invasive Cardiology, 2015, 27, 447.	0.4	1
1015	Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome. Thrombosis and Haemostasis, 2014, 111, 1141-1152.	3.4	26
1016	Association of Severe Obstructive Sleep Apnea and Elevated Blood Pressure Despite Antihypertensive Medication Use. Journal of Clinical Sleep Medicine, 2014, 10, 835-843.	2.6	84
1017	Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation in Stented Renal Arteries. Circulation: Cardiovascular Interventions, 2014, 7, 813-820.	3.9	19
1018	Quality of Care and Outcomes for In-Hospital Ischemic Stroke. Stroke, 2014, 45, 231-238.	2.0	87
1019	Endovascular Therapy for Stroke. Circulation, 2014, 129, 1152-1160.	1.6	15
1020	Clinical Trials in Peripheral Vascular Disease. Circulation, 2014, 130, 1812-1819.	1.6	40
1021	Explaining Unexplained Dyspnea. Circulation, 2014, 130, 2057-2066.	1.6	6
1022	Evolving Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Results From a Survey Among <sc>US</sc> Cardiologists. Clinical Cardiology, 2014, 37, 103-107.	1.8	13
1023	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial. American Heart Journal, 2014, 168, 682-689.e1.	2.7	365
1024	In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2014, 7, 585-593.	3.9	49
1025	Nonobstructive Coronary Artery Disease and Risk of Myocardial Infarction. JAMA - Journal of the American Medical Association, 2014, 312, 1754.	7.4	430
1026	Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-Hour Exclusions and Association With Outcome. Stroke, 2014, 45, 2745-2749.	2.0	37

#	ARTICLE	IF	CITATIONS
1027	Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosis. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 1531-1540.	1.8	17
1028	Dual Antiplatelet Therapy After Stent Implantation—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1446.	7.4	2
1029	Door-to-Needle Times for Tissue Plasminogen Activator Administration and Clinical Outcomes in Acute Ischemic Stroke Before and After a Quality Improvement Initiative. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1632.	7.4	469
1030	Renal Artery Revascularization. <i>JAMA Internal Medicine</i> , 2014, 174, 1849.	5.1	34
1031	Racial/Ethnic Differences in Process of Care and Outcomes Among Patients Hospitalized With Intracerebral Hemorrhage. <i>Stroke</i> , 2014, 45, 3243-3250.	2.0	35
1032	Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. <i>Open Heart</i> , 2014, 1, e000068.	2.3	39
1033	Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack. <i>American Journal of Medicine</i> , 2014, 127, 728-738.	1.5	25
1034	Variations in Coronary Artery Disease Secondary Prevention Prescriptions Among Outpatient Cardiology Practices. <i>Journal of the American College of Cardiology</i> , 2014, 63, 539-546.	2.8	81
1035	Unintentional overestimation of an expected antihypertensive effect in drug and device trials: Mechanisms and solutions. <i>International Journal of Cardiology</i> , 2014, 172, 29-35.	1.7	31
1036	Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2014, 63, 619-629.	2.8	92
1037	Impact of Smoking on Long-Term Outcomes in Patients With Atherosclerotic Vascular Disease Treated With Aspirin or Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2014, 63, 769-777.	2.8	47
1038	Predictors of health care use among patients with or at high risk of atherothrombotic disease: Two-year follow-up data. <i>International Journal of Cardiology</i> , 2014, 175, 72-77.	1.7	6
1039	Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 3-Year Outcomes. <i>New England Journal of Medicine</i> , 2014, 370, 2002-2013.	27.0	1,369
1040	Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure. <i>European Heart Journal</i> , 2014, 35, 1760-1768.	2.2	25
1041	Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin—Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. <i>American Heart Journal</i> , 2014, 167, 437-444.e5.	2.7	89
1042	Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. <i>International Journal of Cardiology</i> , 2014, 170, 413-418.	1.7	64
1043	NSAID Use and Association with Cardiovascular Outcomes in Outpatients with Stable Atherothrombotic Disease. <i>American Journal of Medicine</i> , 2014, 127, 53-60.e1.	1.5	43
1044	Strategies Used by Hospitals to Improve Speed of Tissue-Type Plasminogen Activator Treatment in Acute Ischemic Stroke. <i>Stroke</i> , 2014, 45, 1387-1395.	2.0	81

#	ARTICLE	IF	CITATIONS
1045	Non-adherence to cardiovascular medications. <i>European Heart Journal</i> , 2014, 35, 3267-3276.	2.2	188
1046	Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. <i>Circulation</i> , 2014, 130, 1579-1588.	1.6	594
1047	Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. <i>European Heart Journal</i> , 2014, 35, 2864-2872.	2.2	238
1048	Chronic Kidney Disease and Bleeding Complications After Intravenous Thrombolytic Therapy for Acute Ischemic Stroke. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 929-935.	2.2	35
1049	β ₂ -Blockers and Cardiovascular Events in Patients With and Without Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 872-881.	2.2	84
1050	Do Dipeptidyl Peptidase-4 Inhibitors Increase the Risk of Heart Failure?. <i>JACC: Heart Failure</i> , 2014, 2, 583-585.	4.1	23
1051	Race/Ethnic Differences in the Risk of Hemorrhagic Complications Among Patients With Ischemic Stroke Receiving Thrombolytic Therapy. <i>Stroke</i> , 2014, 45, 2263-2269.	2.0	81
1052	Insurance Status and Outcome after Intracerebral Hemorrhage: Findings from Get With The Guidelines-Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, 283-292.	1.6	31
1053	Hospital patterns of medical management strategy use for patients with non-“ST-elevation myocardial infarction and 3-vessel or left main coronary artery disease. <i>American Heart Journal</i> , 2014, 167, 355-362.e3.	2.7	11
1054	Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction. <i>American Heart Journal</i> , 2014, 167, 840-845.	2.7	16
1055	Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy. <i>Thrombosis Research</i> , 2014, 134, 96-104.	1.7	5
1056	Conductance sizing balloon for measurement of peripheral artery minimal stent area. <i>Journal of Vascular Surgery</i> , 2014, 60, 759-766.	1.1	5
1057	Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes. <i>Circulation Research</i> , 2014, 114, 1929-1943.	4.5	79
1058	CPAP versus Oxygen in Obstructive Sleep Apnea. <i>New England Journal of Medicine</i> , 2014, 370, 2276-2285.	27.0	294
1059	A Controlled Trial of Renal Denervation for Resistant Hypertension. <i>New England Journal of Medicine</i> , 2014, 370, 1393-1401.	27.0	1,848
1060	Clopidogrel prescription filling delays and cardiovascular outcomes in a pharmacy system integrating inpatient and outpatient care: Insights from the Veterans Affairs CART Program. <i>American Heart Journal</i> , 2014, 168, 340-345.	2.7	5
1061	Current quality of cardiovascular prevention for Million Hearts: An analysis of 147,038 outpatients from The Guideline Advantage. <i>American Heart Journal</i> , 2014, 168, 398-404.	2.7	26
1062	Platelet Inhibition with Cangrelor during PCI. <i>New England Journal of Medicine</i> , 2013, 369, 393-394.	27.0	14

#	ARTICLE	IF	CITATIONS
1063	Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine, 2013, 369, 1317-1326.	27.0	3,017
1064	Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet, The, 2013, 382, 1981-1992.	13.7	286
1065	Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents. JAMA - Journal of the American Medical Association, 2013, 310, 2510-22.	7.4	513
1066	Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. Journal of the American College of Cardiology, 2013, 62, 2261-2273.	2.8	807
1067	Patient and Hospital Characteristics Associated With Inappropriate Percutaneous Coronary Interventions. Journal of the American College of Cardiology, 2013, 62, 2274-2281.	2.8	32
1068	Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors. International Journal of Cardiology, 2013, 163, 266-271.	1.7	21
1069	Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet, The, 2013, 382, 605-613.	13.7	105
1070	Is It Cost-Effective To Increase Aspirin Use in Outpatient Settings for Primary or Secondary Prevention? Simulation Data from the REACH Registry Australian Cohort. Cardiovascular Therapeutics, 2013, 31, 45-52.	2.5	8
1071	Are All Clinical Trial Sites Created Equal?. Journal of the American College of Cardiology, 2013, 61, 580-581.	2.8	11
1072	Racial/Ethnic Differences in B-Type Natriuretic Peptide Levels and Their Association With Care and Outcomes Among Patients Hospitalized With Heart Failure. JACC: Heart Failure, 2013, 1, 345-352.	4.1	32
1073	Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-Medications (Including) Tj ETQq1 1 0.784314 rgBT /Over College of Cardiology, 2013, 61, 872-879.	2.8	170
1074	Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51. Journal of the American College of Cardiology, 2013, 62, 286-290.	2.8	88
1075	Adjunctive Pharmacotherapy for Thrombotic Coronary Lesions. Interventional Cardiology Clinics, 2013, 2, 375-387.	0.4	0
1076	Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. New England Journal of Medicine, 2013, 368, 1303-1313.	27.0	695
1077	Conduits in Coronary Artery Bypass Grafting. Seminars in Thoracic and Cardiovascular Surgery, 2013, 25, 273-279.	0.6	3
1078	Carotid Atherosclerosis and Risk of Subsequent Coronary Event in Outpatients With Atherothrombosis. Stroke, 2013, 44, 373-379.	2.0	65
1079	A History of Stroke/Transient Ischemic Attack Indicates High Risks of Cardiovascular Event and Hemorrhagic Stroke in Patients With Coronary Artery Disease. Circulation, 2013, 127, 730-738.	1.6	74
1080	Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines® Stroke Hospitals. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 543-549.	2.2	247

#	ARTICLE	IF	CITATIONS
1081	Achievement of Guideline-Concordant Care and In-Hospital Outcomes in Patients With Coronary Artery Disease in Teaching and Nonteaching Hospitals. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 58-65.	2.2	25
1082	Predictors of Long-term Adherence to Evidence-based Cardiovascular Disease Medications in Outpatients With Stable Atherothrombotic Disease: Findings From the <scp>REACH</scp> Registry. <i>Clinical Cardiology</i> , 2013, 36, 721-727.	1.8	72
1083	Differences in the Profile, Treatment, and Prognosis of Patients With Cardiogenic Shock by Myocardial Infarction Classification. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 708-715.	2.2	100
1084	Synthesizing Lessons Learned From Get With The Guidelines. <i>Circulation</i> , 2013, 128, 2447-2460.	1.6	106
1085	Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. <i>European Heart Journal</i> , 2013, 34, 1204-1214.	2.2	167
1086	Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines-Stroke Hospitals. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 543-549.	2.2	132
1087	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. <i>New England Journal of Medicine</i> , 2012, 367, 1297-1309.	27.0	765
1088	β-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1340.	7.4	377
1089	Polyvascular Disease and Long-Term Cardiovascular Outcomes in Older Patients With Non-“ST-Segment” Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 541-549.	2.2	65
1090	Clinical Outcomes Using a Platelet Function-Guided Approach for Secondary Prevention in Patients With Ischemic Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2012, 43, 2376-2381.	2.0	47
1091	Response to Letter Regarding Article “Clinical Outcomes Using a Platelet Function-Guided Approach for Secondary Prevention in Patients With Ischemic Stroke or Transient Ischemic Attack”. <i>Stroke</i> , 2012, 43, .	2.0	0
1092	The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. <i>European Heart Journal</i> , 2012, 33, 2143-2150.	2.2	86
1093	Antiplatelet Therapy Following Myocardial Infarction in Patients With Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 921.	7.4	11
1094	EXAMINATION of new drug-eluting stents—top of the class!. <i>Lancet, The</i> , 2012, 380, 1453-1455.	13.7	32
1095	Fate of individuals with ischemic amputations in the REACH Registry: Three-year cardiovascular and limb-related outcomes. <i>Atherosclerosis</i> , 2012, 221, 527-535.	0.8	46
1096	Antiplatelet Therapy and Proton Pump Inhibition. <i>Circulation</i> , 2012, 125, 375-380.	1.6	46
1097	Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. <i>American Heart Journal</i> , 2012, 163, 182-190.e4.	2.7	89
1098	Rationale and design of the Cangrelor versus standard therapy to achieve optimal Management of Platelet Inhibition PHOENIX trial. <i>American Heart Journal</i> , 2012, 163, 768-776.e2.	2.7	72

#	ARTICLE	IF	CITATIONS
1099	An International Model to Predict Recurrent Cardiovascular Disease. American Journal of Medicine, 2012, 125, 695-703.e1.	1.5	184
1100	Clopidogrel resistance – A clear problem with an unclear solution. Indian Heart Journal, 2012, 64, 353-355.	0.5	4
1101	A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers. Journal of the American College of Cardiology, 2012, 59, 1304-1311.	2.8	120
1102	Age and Gender Differences in Quality of Care and Outcomes for Patients with ST-segment Elevation Myocardial Infarction. American Journal of Medicine, 2012, 125, 1000-1009.	1.5	128
1103	Living Alone and Cardiovascular Risk in Outpatients at Risk of or With Atherothrombosis. Archives of Internal Medicine, 2012, 172, 1086.	3.8	109
1104	Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. New England Journal of Medicine, 2012, 366, 9-19.	27.0	1,681
1105	Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. New England Journal of Medicine, 2012, 366, 1567-1576.	27.0	1,973
1106	Statin and Aspirin Therapy for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. Clinical Cardiology, 2012, 35, 722-729.	1.8	19
1107	Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. Journal of Thrombosis and Thrombolysis, 2012, 34, 44-55.	2.1	131
1108	The promise of renal denervation. Cleveland Clinic Journal of Medicine, 2012, 79, 498-500.	1.3	17
1109	Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Non-Compliance, Diet, Smoking, Co-Medications (including) Tj ETQq1 1104784314rgBT /Ove		
1110	Changes in Myocardial Infarction Guideline Adherence as a Function of Patient Risk. Journal of the American College of Cardiology, 2011, 58, 1760-1765.	2.8	42
1111	Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. Thrombosis and Haemostasis, 2011, 106, 571-584.	3.4	188
1112	Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. New England Journal of Medicine, 2011, 365, 699-708.	27.0	918
1113	The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus – Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study. American Heart Journal, 2011, 162, 818-825.e6.	2.7	98
1114	Economic Evaluation of Clopidogrel Plus Aspirin for Secondary Prevention of Cardiovascular Events in Canada for Patients With Established Cardiovascular Disease: Results From the CHARISMA Trial. Canadian Journal of Cardiology, 2011, 27, 222-231.	1.7	2
1115	Treatment with w-3 fatty acids reduces serum C-reactive protein concentration. Clinical Lipidology, 2011, 6, 723-729.	0.4	6
1116	Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke. Circulation, 2011, 123, 750-758.	1.6	510

#	ARTICLE	IF	CITATIONS
1117	Standardized Bleeding Definitions for Cardiovascular Clinical Trials. <i>Circulation</i> , 2011, 123, 2736-2747.	1.6	3,378
1118	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Coronary Stenting. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 522-534.	3.9	103
1119	Right Heart Catheterization, Coronary Angiography, and Percutaneous Coronary Intervention. <i>Circulation</i> , 2011, 124, e428-33.	1.6	21
1120	Low-Dose Aspirin-Induced Ulceration Is Attenuated by Aspirin-Phosphatidylcholine: A Randomized Clinical Trial. <i>American Journal of Gastroenterology</i> , 2011, 106, 272-277.	0.4	83
1121	Risk factors and outcomes for patients with vascular disease and serious bleeding events. <i>Heart</i> , 2011, 97, 1507-1512.	2.9	28
1122	Prevalence and treatment of cardiovascular risk factors in outpatients with atherothrombosis in the Middle East. <i>Heart Asia</i> , 2011, 3, 77-81.	1.1	5
1123	Current Use of Aspirin and Antithrombotic Agents in the United States Among Outpatients With Atherothrombotic Disease (from the REduction of Atherothrombosis for Continued Health [REACH]) Tj ETQq1 1 0.784314 reg BT /Overl	1.6	60
1124	Cardiovascular Event Rates in Diabetic and Nondiabetic Individuals With and Without Established Atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). <i>American Journal of Cardiology</i> , 2010, 105, 667-671.	1.6	60
1125	Atherothrombosis and atrial fibrillation: Important and often overlapping clinical syndromes. <i>Thrombosis and Haemostasis</i> , 2010, 104, 657-663.	3.4	67
1126	Metformin Use and Mortality Among Patients With Diabetes and Atherothrombosis<alt-title>Metformin Use With Diabetes and Atherothrombosis</alt-title>. <i>Archives of Internal Medicine</i> , 2010, 170, 1892.	3.8	319
1127	ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. <i>Circulation</i> , 2010, 122, 2619-2633.	1.6	281
1128	Response to Letter Regarding Article, "Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease". <i>Circulation</i> , 2010, 122, .	1.6	0
1129	Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1350.	7.4	626
1130	Advancing the Care of Cardiac Patients Using Registry Data. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 2188.	7.4	39
1131	Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. <i>Nature Reviews Cardiology</i> , 2010, 7, 461-467.	13.7	38
1132	Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. <i>European Heart Journal</i> , 2010, 31, 1257-1265.	2.2	119
1133	Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment. <i>New England Journal of Medicine</i> , 2010, 363, 1704-1714.	27.0	497
1134	Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate. <i>Journal of the American College of Cardiology</i> , 2010, 56, 919-933.	2.8	1,058

#	ARTICLE	IF	CITATIONS
1135	ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Journal of the American College of Cardiology, 2010, 56, 2051-2066.	2.8	203
1136	Clopidogrel with or without Omeprazole in Coronary Artery Disease. New England Journal of Medicine, 2010, 363, 1909-1917.	27.0	1,019
1137	Platelet aspirin resistance in ED patients with suspected acute coronary syndrome. American Journal of Emergency Medicine, 2010, 28, 440-444.	1.6	7
1138	Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet, The, 2010, 376, 517-523.	13.7	222
1139	Controversies in non-ST-elevation acute coronary syndromes and percutaneous coronary interventions. Cleveland Clinic Journal of Medicine, 2010, 77, 101-109.	1.3	1
1140	Predictive value of high sensitivity C-reactive protein in the diagnosis and outcomes of acute aortic syndromes. Heart Asia, 2010, 2, 136-9.	1.1	7
1141	Intravenous Platelet Blockade with Cangrelor during PCI. New England Journal of Medicine, 2009, 361, 2330-2341.	27.0	560
1142	Platelet Inhibition with Cangrelor in Patients Undergoing PCI. New England Journal of Medicine, 2009, 361, 2318-2329.	27.0	533
1143	Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome. Circulation, 2009, 119, 2877-2885.	1.6	428
1144	Tailoring Antiplatelet Therapy Based on Pharmacogenomics. JAMA - Journal of the American Medical Association, 2009, 302, 896.	7.4	40
1145	Response to Letter Regarding Article, "Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Risk" Circulation, 2009, 119, .	1.6	3
1146	Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. European Heart Journal, 2009, 30, 1195-1202.	2.2	157
1147	Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. European Heart Journal, 2009, 30, 2318-2326.	2.2	277
1148	Prasugrel in Clinical Practice. New England Journal of Medicine, 2009, 361, 940-942.	27.0	81
1149	Quality of Care for Acute Coronary Syndrome Patients With Known Atherosclerotic Disease. Circulation, 2009, 120, 560-567.	1.6	68
1150	Association of Hospital Primary Angioplasty Volume in ST-Segment Elevation Myocardial Infarction With Quality and Outcomes. JAMA - Journal of the American Medical Association, 2009, 302, 2207.	7.4	83
1151	Role of Antiplatelet Therapy Across the Spectrum of Patients with Coronary Artery Disease. American Journal of Cardiology, 2009, 103, 11A-19A.	1.6	24
1152	Patient Characteristics Associated With the Choice of Triple Antithrombotic Therapy in Acute Coronary Syndromes. American Journal of Cardiology, 2009, 104, 1171-1178.	1.6	25

#	ARTICLE	IF	CITATIONS
1153	Cost-Effectiveness of Clopidogrel plus Aspirin versus Aspirin Alone for Secondary Prevention of Cardiovascular Events: Results from the CHARISMA Trial. <i>Value in Health</i> , 2009, 12, 872-879.	0.3	29
1154	Ticagrelor in ACS—what does PLATO teach us?. <i>Nature Reviews Cardiology</i> , 2009, 6, 737-738.	13.7	18
1155	Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. <i>Atherosclerosis</i> , 2009, 204, e86-e92.	0.8	220
1156	Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding. <i>Annals of Internal Medicine</i> , 2009, 150, 379.	3.9	152
1157	Platelet response in practice: Applying new insights and tools for testing and treatment. <i>Cleveland Clinic Journal of Medicine</i> , 2009, 76, S24-S32.	1.3	0
1158	Percutaneous coronary intervention in nonagenarians: Age before beauty?. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 71, 531-532.	1.7	5
1159	Introduction. <i>American Journal of Cardiology</i> , 2008, 101, S1-S2.	1.6	6
1160	Anti-Inflammatory Agents and Antioxidants as a Possible “Third Great Wave” in Cardiovascular Secondary Prevention. <i>American Journal of Cardiology</i> , 2008, 101, S4-S13.	1.6	44
1161	ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1502-1517.	2.8	390
1162	Culprit-only or multivessel revascularization in patients with acute coronary syndromes. <i>American Heart Journal</i> , 2008, 155, 140-146.	2.7	115
1163	Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. <i>American Heart Journal</i> , 2008, 156, 855-863.e2.	2.7	243
1164	Aspirin and Platelet Adenosine Diphosphate Receptor Antagonists in Acute Coronary Syndromes and Percutaneous Coronary Intervention. <i>American Journal of Cardiovascular Drugs</i> , 2008, 8, 91-112.	2.2	21
1165	ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. <i>Circulation</i> , 2008, 118, 1894-1909.	1.6	563
1166	Patients with peripheral arterial disease in the CHARISMA trial. <i>European Heart Journal</i> , 2008, 30, 192-201.	2.2	290
1167	Is prasugrel superior to clopidogrel for patients with acute coronary syndromes undergoing PCI?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 252-253.	3.3	4
1168	Intensifying Platelet Inhibition — Navigating between Scylla and Charybdis. <i>New England Journal of Medicine</i> , 2007, 357, 2078-2081.	27.0	164
1169	One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1197.	7.4	1,162
1170	Peroxisome proliferator-activated receptor β agonists for the Prevention of Adverse events following percutaneous coronary Revascularization—results of the PPAR Study. <i>American Heart Journal</i> , 2007, 154, 137-143.	2.7	31

#	ARTICLE	IF	CITATIONS
1171	A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. European Heart Journal, 2007, 28, 664-672.	2.2	115
1172	Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. Journal of the American College of Cardiology, 2007, 49, 1982-1988.	2.8	752
1173	Presence of Carotid and Peripheral Arterial Disease in Patients With Left Main Disease. American Journal of Cardiology, 2007, 100, 1087-1089.	1.6	26
1174	Interpreting the COURAGE trial. Is medical therapy as good as PCI in stable angina? Two views.. Cleveland Clinic Journal of Medicine, 2007, 74, 618-618.	1.3	3
1175	Clopidogrel Bisulfate In ST-Segment Elevation Myocardial Infarction. American Journal of Cardiovascular Drugs, 2006, 6, 415-416.	2.2	2
1176	The Influence of Peripheral Arterial Disease on Outcomes. Journal of the American College of Cardiology, 2006, 48, 1567-1572.	2.8	152
1177	Benefit of Early Invasive Therapy in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2006, 48, 1319-1325.	2.8	496
1178	The REduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. American Heart Journal, 2006, 151, 786.e1-786.e10.	2.7	235
1179	Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. American Heart Journal, 2006, 151, 976.e7-976.e11.	2.7	32
1180	Identification of and Management Approaches for the High-Risk Patient. American Journal of Cardiology, 2006, 98, S22-S29.	1.6	4
1181	Can clopidogrel and aspirin lower mortality in patients with acute myocardial infarction?. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 182-183.	3.3	6
1182	International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis. JAMA - Journal of the American Medical Association, 2006, 295, 180.	7.4	1,353
1183	Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. New England Journal of Medicine, 2006, 354, 1706-1717.	27.0	2,582
1184	Aspirin and clopidogrel resistance: an emerging clinical entity. European Heart Journal, 2006, 27, 647-654.	2.2	286
1185	Using statins to treat inflammation in acute coronary syndromes: Are we there yet?. Cleveland Clinic Journal of Medicine, 2006, 73, 760-766.	1.3	14
1186	Analysis of Risk of Bleeding Complications After Different Doses of Aspirin in 192,036 Patients Enrolled in 31 Randomized Controlled Trials. American Journal of Cardiology, 2005, 95, 1218-1222.	1.6	304
1187	Periprocedural Cardiac Enzyme Elevation Predicts Adverse Outcomes. Circulation, 2005, 112, 906-922.	1.6	129
1188	Effects of Clopidogrel and Aspirin in Combination Versus Aspirin Alone on Platelet Activation and Major Receptor Expression in Patients After Recent Ischemic Stroke. Stroke, 2005, 36, 2289-2292.	2.0	64

#	ARTICLE	IF	CITATIONS
1189	A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American Heart Journal, 2005, 150, 401.e1-401.e7.	2.7	29
1190	Issues in the management of antiplatelet therapy in patients undergoing surgical revascularization. A roundtable discussion. Journal of Invasive Cardiology, 2005, 17, 283-7.	0.4	2
1191	Benefit of Clopidogrel Over Aspirin Is Amplified in Patients With a History of Ischemic Events. Stroke, 2004, 35, 528-532.	2.0	190
1192	Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations. Archives of Internal Medicine, 2004, 164, 2106.	3.8	119
1193	Utilization of Early Invasive Management Strategies for High-Risk Patients With Non-“ST-Segment Elevation Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2004, 292, 2096.	7.4	525
1194	Aspirin dose and six-month outcome after an acute coronary syndrome. Journal of the American College of Cardiology, 2004, 43, 972-978.	2.8	54
1195	Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American Heart Journal, 2004, 148, 263-268.	2.7	193
1196	Peripheral Arterial Disease in the Catheterization Laboratory: An Underdetected and Undertreated Risk Factor. Mayo Clinic Proceedings, 2004, 79, 1107-1109.	3.0	13
1197	An international prospective observational registry in subjects at risk of atherothrombotic events. Japanese Journal of Thrombosis and Hemostasis, 2004, 15, 376-382.	0.1	0
1198	Embolization—a pathological mechanism in renal artery stenosis. Journal of Invasive Cardiology, 2004, 16, 196-7.	0.4	4
1199	Asymptomatic acute inferior ST elevation myocardial infarction from thermal injury complicating radiofrequency ablation for atrioventricular re-entrant tachycardia. Journal of Invasive Cardiology, 2004, 16, 504-5.	0.4	5
1200	Bleeding complications during percutaneous coronary intervention. Journal of Invasive Cardiology, 2004, 16, 24S-29S.	0.4	0
1201	Emboli protection devices. Journal of Invasive Cardiology, 2004, 16, 45S-49S.	0.4	0
1202	Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes. American Journal of Cardiology, 2003, 92, 136-140.	1.6	39
1203	Scientific and therapeutic advances in antiplatelet therapy. Nature Reviews Drug Discovery, 2003, 2, 15-28.	46.4	346
1204	Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: Results of the coronary revascularization using integrilin and single bolus enoxaparin study. Journal of the American College of Cardiology, 2003, 41, 20-25.	2.8	86
1205	Relation of Inflammation and Benefit of Statins After Percutaneous Coronary Interventions. Circulation, 2003, 107, 1750-1756.	1.6	195
1206	Aspirin and Clopidogrel in Acute Coronary Syndromes. Archives of Internal Medicine, 2003, 163, 1145.	3.8	79

#	ARTICLE	IF	CITATIONS
1207	Using C-reactive protein to assess cardiovascular disease risk.. Cleveland Clinic Journal of Medicine, 2003, 70, 634-640.	1.3	43
1208	Diffuse coronary disease and atherothrombosis: a rationale for long-term therapy to prevent recurrent ischemic events. Journal of Invasive Cardiology, 2003, 15 Suppl B, 3B-9B; discussion 9B-10B.	0.4	6
1209	Heparin in peripheral vascular intervention--time for a change?. Journal of Invasive Cardiology, 2003, 15, 249-50.	0.4	2
1210	Early and Sustained Survival Benefit Associated With Statin Therapy at the Time of Percutaneous Coronary Intervention. Circulation, 2002, 105, 691-696.	1.6	237
1211	Need to Test the Arterial Inflammation Hypothesis. Circulation, 2002, 106, 136-140.	1.6	137
1212	Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. Journal of the American College of Cardiology, 2002, 39, 9-14.	2.8	313
1213	Successful "pre-closure" of 7Fr and 8Fr femoral arteriotomies with a 6Fr suture-based device (the Tj ETQq1 1 0.784314 rBT /Over	1.6	14
1214	Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. American Journal of Cardiology, 2002, 90, 625-628.	1.6	376
1215	Oral Glycoprotein IIb/IIIa Inhibitors. American Journal of Cardiovascular Drugs, 2001, 1, 421-428.	2.2	39
1216	Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists. Circulation, 2001, 103, 201-206.	1.6	359
1217	Initial Experience of Platelet Glycoprotein IIb/IIIa Inhibition With Abciximab During Carotid Stenting. Stroke, 2001, 32, 2328-2332.	2.0	79
1218	Oral glycoprotein IIb/IIIa antagonists in coronary artery disease. Current Cardiology Reports, 2001, 3, 63-71.	2.9	13
1219	Superiority of Clopidogrel Versus Aspirin in Patients With Prior Cardiac Surgery. Circulation, 2001, 103, 363-368.	1.6	266
1220	Incremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary Intervention. Circulation, 2001, 104, 992-997.	1.6	241
1221	Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention. Circulation, 2001, 103, 961-966.	1.6	336
1222	Attenuation of Rebound Ischemia After Discontinuation of Heparin Therapy by Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Acute Coronary Syndromes. Circulation, 2001, 104, 2772-2777.	1.6	36
1223	Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2000, 284, 1549.	7.4	238
1224	Pronounced Benefit of Coronary Stenting and Adjunctive Platelet Glycoprotein IIb/IIIa Inhibition in Complex Atherosclerotic Lesions. Circulation, 2000, 102, 28-34.	1.6	69

#	ARTICLE	IF	CITATIONS
1225	Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. American Heart Journal, 2000, 140, 67-73.	2.7	133
1226	Abciximab reduces mortality in diabetics following percutaneous coronary intervention. Journal of the American College of Cardiology, 2000, 35, 922-928.	2.8	312
1227	Antiplatelet Therapy in Chronic Coronary Artery Disease. , 0, , 178-195.		0
1228	Substantial Impact of Eicosapentaenoic Acid on Cardiovascular Outcomes in the REDUCE-IT Trial. Cardiometabolic Syndrome Journal, 0, 2, .	0.6	0
1229	Cardiovascular meta-analyses: foolâ€™s gold or gold for fools?. European Heart Journal, 0, , .	2.2	0